

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

Acid, fatty,

- Essential fatty acids in the plasma phospholipids of patients with leprosy. Wright, S. . . (A) 677
 Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* (A) 508
 Quantitative comparison of the mycolic and fatty acid compositions of *Mycobacterium leprae* and *M. gordonae*. Minnikin, D. E., *et al.* (A) 687

Adenosine triphosphatase (ATP),

- Application of ATP assays to patient care in leprosy. Dhople, A. M. (A) 507
 Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., *et al.* (A) 698
 Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* (O) 365

Africa,

- Leprosy in Africans. A Pictorial Documentation Based on Photographs Selected and Annotated by W. K. Jacyk.* (B) 130

Anemia,

- Dapsone and aplastic anemia. Foucauld, J., *et al.* (A) 327
 Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., *et al.* (A) 672

Antibody(ies),

- A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. (A) 138
 Absence from sera from normal individuals' or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O) 22
 Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae*. Gillis, T. P. (A) 718
 Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* (A) 503
 Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* (A) 144
 Anti-*Mycobacterium leprae* antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., *et al.* (A) 336
 Antibodies to *Mycobacterium leprae* detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* (A) 354
 Antibody response to phenolic glycolipid-I in inbred mice immunized with *Mycobacterium leprae*. Teuscher, C., *et al.* (A) 683
 Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. (A) 348
 Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., *et al.* (O) 211
 Characterization of competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae*. Gillis, T. P., *et al.* (A) 178
 Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* (A) 175
 Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., *et al.* (O) 565
 Determination of inhibitory concentrations of antiviral agents in cell culture by use of

- an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* (A) 699
- Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* (A) 506
- Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* (A) 137
- Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* (A) 165
- Evaluation of tubercular antigen and antitubercular antibodies in pleural and ascitic effusions. Samuel, A. M., *et al.* (A) 514
- Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* (A) 339
- Human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T., *et al.* (A) 677
- IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* (A) 341
- In situ* identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* (A) 503
- Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., *et al.* (O) 218
- Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. (E) 618
- Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae*. Young, D. B., *et al.* (A) 684
- Myelinotoxic effect of serum antibodies from leprosy patients. Umerov, G. G., *et al.* .. (A) 506
- Neural auto-antibodies in leprosy. Eustis-Turf, E. P., *et al.* (A) 722
- Production and characterization of monoclonal antibodies to *Mycobacterium tuberculosis*. Kolk, A. H. J., *et al.* (A) 338
- Production of human antibodies to *Mycobacterium leprae*. Mohaghehpour, N., *et al.* (A) 717
- Production of human monoclonal antibodies to *Mycobacterium leprae*. Mohaghehpour, N., *et al.* (A) 178
- Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. (A) 682
- Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., *et al.* (A) 363
- Salivary anti-*M. leprae* antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., *et al.* (A) 715
- Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* (A) 360
- Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* (O) 33
- Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. (A) 715
- Strain variation of lymphokine production and specific antibody secretion in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* (A) 510
- The molecular basis of positive treponemal antibody, antinuclear antibody, and immune complex tests among Hansen's disease patients. Miller, R. A., *et al.* (A) 713
- The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae*. Ji, B., *et al.* (A) 357
- The study of antibodies to DNA in the patients with complicated lepromatous leprosy. Kuzina, Z. A. (A) 499
- Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., *et al.* (O) 373
- Antigen(s),**
- A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. (A) 506
- A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. (A) 138

Detection of an antigen (MY4) common to <i>M. tuberculosis</i> and <i>M. leprae</i> by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. (A)	681
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	175
Dissection of <i>Mycobacterium tuberculosis</i> antigens using recombinant DNA. Young, R. A., <i>et al.</i> (A)	699
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., <i>et al.</i> (A)	165
Evaluation of tubercular antigen and antitubercular antibodies in pleural and ascitic effusions. Samuel, A. M., <i>et al.</i> (A)	514
Host responses to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	710
Immunologic assessment of <i>Mycobacterium leprae</i> antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. (A)	173
<i>In vivo</i> responses to <i>Mycobacterium leprae</i> : antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., <i>et al.</i> (O)	385
Isolation and preliminary characterization of the major intracellular carbohydrate-containing antigens of <i>Mycobacterium leprae</i> . Hunter, S. W., <i>et al.</i> (A)	712
Monoclonal antibodies to a 28,000 mol. wt protein antigen of <i>Mycobacterium leprae</i> . Young, D. B., <i>et al.</i> (A)	684
Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., <i>et al.</i> (A)	514
New-found glycolipid antigens of mycobacteria. Brennan, P. J. (A)	343
Occurrence of antigen BCG 60 in leprosy-derived corynebacteria and other coryneforms. Papa, F. P., <i>et al.</i> (A)	345
Parasitism of antigen presenting cells in hyperbacillary leprosy. Poulter, L. W., <i>et al.</i> (A)	505
Protective properties of some bacterial antigens in experimental leprosy. Zajcev, R. A. and Umerov, G. G. (A)	506
Recombinant DNA clones expressing <i>M. leprae</i> and <i>M. tuberculosis</i> antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., <i>et al.</i> (A)	727
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
Strain variation in murine immune response to the <i>M. leprae</i> glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., <i>et al.</i> (A)	721
Use of an artificial antigen containing the 3,6-di- <i>O</i> -methyl- β -D-glucopyranosyl epitope for the serodiagnosis of leprosy. Cho, S.-N., <i>et al.</i> (A)	139
Argentina,	
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
Armadillo(s),	
A possible mode of transmission of armadillo leprosy in the wild and a simple method to conduct a random survey of its prevalence. Job, C. K., <i>et al.</i> (A)	723
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., <i>et al.</i> (A)	724
Biochemical alterations in the serum of armadillos (<i>Dasypus novemcinctus</i>) infected with <i>Mycobacterium leprae</i> . A preliminary report. Rojas-Espinosa, O., <i>et al.</i> (O)	262
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	687
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	175
Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., <i>et al.</i> (A)	352
Experimental reproduction of leprosy in seven-banded armadillos (<i>Dasypus hybridus</i>). Balina, L. M., <i>et al.</i> (O)	595
First lesion in experimental armadillo leprosy. Job, C. K., <i>et al.</i> (A)	690

Leprosy in wild armadillos (<i>Dasypus novemcinctus</i>) of the Texas Gulf Coast. Smith, J. H., <i>et al.</i> (A)	358
Manifestation of experimental leprosy in the armadillo. Job, C. K., <i>et al.</i> (A)	350
Phagocytosis of <i>Mycobacterium leprae</i> and <i>M. avium</i> by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. (A)	340
Presence of "difficult-to-grow" mycobacteria in armadillos. Dhople, A. M., <i>et al.</i> (A)	166
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., <i>et al.</i> (C)	484
Reversal reactions in <i>M. leprae</i> -infected nine-banded armadillos. Juscenko, A. A. (A)	510
The adenosine triphosphate content and death rate of <i>Mycobacterium leprae</i> isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., <i>et al.</i> (A)	169
The free lipids of <i>Mycobacterium leprae</i> harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., <i>et al.</i> (A)	686
Ultrastructure of sciatic nerve of armadillo infected with <i>Mycobacterium leprae</i> . Mehta, L. N. and Antia, N. H. (A)	338
Use of gas chromatography to differentiate <i>Mycobacterium leprae</i> from cultivable armadillo-derived mycobacteria, <i>M. avium/intracellulare</i> , and <i>M. lepraemurium</i> by analysis of secondary alcohols. Larsson, L., <i>et al.</i> (O)	441
Armed Forces,	
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. (A)	693
Leprosy in the Armed Forces of the United States: newly reported cases from 1970 to 1983. Schlagel, C. J., <i>et al.</i> (A)	692
Arthritis,	
Thalidomide. A promising new treatment for rheumatoid arthritis. Gutierrez-Rodriguez, O. (A)	151
Asia,	
Proceedings of the 5th International Workshop on Leprosy Control in Asia. Leprosy Control in Urban Community. (B)	323
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Specific health problems of Southeast Asian refugees in middle Tennessee. Dao, A. H., <i>et al.</i> (A)	132
Assay(s) (see also ELISA),	
Application of ATP assays to patient care in leprosy. Dhople, A. M. (A)	507
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for <i>Mycobacterium leprae</i> . Gillis, T. P., <i>et al.</i> (A)	178
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of <i>Mycobacterium leprae</i> sensitivity/resistance to dapsone. Sathish, M., <i>et al.</i> (O)	378
Deoxyribonucleic acid relatedness among <i>Mycobacterium leprae</i> , <i>Mycobacterium lepraemurium</i> , and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., <i>et al.</i> (A)	342
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., <i>et al.</i> (O)	565
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti- <i>M. leprae</i> antibodies. Sukhenko, L. T., <i>et al.</i> (A)	506
Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., <i>et al.</i> (A)	698
Rapid, radiometric <i>in vitro</i> assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., <i>et al.</i> (A)	670
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360

a suppressor mechanism or expansion of a small <i>M. leprae</i> -reactive T-cell pool? Shankar, P., <i>et al.</i>	(C)	649
Low prevalence of serologic evidence of polyclonal B cell activation among Hansen's disease patients in Seattle. Miller, R. A., <i>et al.</i>	(A)	182
<i>Mycobacterium leprae</i> within a squamous cell carcinoma. Laing, A. B. G., <i>et al.</i>	(A)	333
Normal numbers of T6 positive epidermal Langerhans' cells across the leprosy spectrum. Narayanan, R. B., <i>et al.</i>	(A)	143
Parasitism of antigen presenting cells in hyperbacillary leprosy. Poulter, L. W., <i>et al.</i>	(A)	505
Persistence of Langerhans' giant cells in rapidly downgrading leprosy lesions. Lyons, N. F., <i>et al.</i>	(C)	114
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta- Palacios, J. J., <i>et al.</i>	(A)	669
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., <i>et al.</i>	(A)	678
Rapid detection of mycobacterial contamination in batches of whole cells of purified <i>Mycobacterium leprae</i> by pyrolysis gas chromatography. Wieten, G., <i>et al.</i>	(A)	348
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L.	(A)	696
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of <i>M. leprae</i> for drug sensitivity testing: a comparison. Seydel, U., <i>et al.</i>	(O)	365
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to <i>Mycobacterium leprae</i> . Haregewoin, A., <i>et al.</i>	(A)	141
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., <i>et al.</i>	(A)	363
Specific suppression of responses to <i>Leishmania tropica</i> by a cloned T-cell line. Liew, F. Y.	(A)	362
Squamous cell carcinoma developing in trophic ulcers in leprosy—a case report. Kumar, K. and Kant, M.	(A)	333
T-cell responsiveness in <i>Mycobacterium lepraemurium</i> infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J.	(A)	349
Thalidomide—effect on T cell subsets as a possible mechanism of action. Moncada, B., <i>et al.</i>	(O)	201
The cell interaction in lepromin test. Ibraimov, M.	(A)	502
The spectrum of <i>in vitro</i> T-cell responsiveness in lepromatous leprosy. Kaplan, G., <i>et</i> <i>al.</i>	(A)	708
Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., <i>et al.</i>	(A)	503
Chemotherapy, see also Therapy,		
A follow-up investigation of the Matla Project. Jopling, W. H., <i>et al.</i>	(A)	134
Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy meeting, 10–11 October 1983.	(N)	125
An anomalous response of <i>M. leprae</i> to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C.	(A)	167
Chemotherapy of Leprosy for Control Programs videotape available.	(N)	126
Chemotherapy of leprosy—a tool for leprosy control (The Kellersberger Memorial Lec- ture, 1984). Levy, L.	(A)	669
ELISA evaluation of phenolic glycolipid-I (PGI) and whole <i>M. leprae</i> with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., <i>et al.</i>	(A)	180
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intra- cellular pathway. Weldon, J. S., <i>et al.</i>	(A)	153
On a role of antileptotic agents as the scavengers of active oxygen radicals. Tsutsumi, S. and Gidoh, M.	(A)	714
Recent Ideas and "Progress in the Treatment" of Leprosy (Erwin Stindl Memorial Oration, 1985). Girdhar, B. K.	(N)	663
Role of dapsone in chemotherapy of leprosy—a comparison of responses to therapy in two cohorts in 1960s and 1970s. Reddy, B. N. and Neelan, P. N.	(A)	497
The chemotherapy of leprosy. Hooper, M. and Purohit, M. G.	(A)	134
Children,		
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., <i>et al.</i>	(A)	143

An epidemiological study of leprosy among children in a rural area (India). Reddy, B. N. and Bansal, R. D. (A)	148
Leprosy in children one year of age and under. Brubaker, M. L., <i>et al.</i> (O)	517
Leprosy in young children—past, present and future. Duncan, M. E. (E)	468
Multibacillary leprosy in an 18-month-old child: a case report. Nsibambi, J., <i>et al.</i> (A)	333
Prevalence of leprosy in children of leprosy parents. Dave, D. S. and Agrawal, S. K. (A)	354
Skin-test sensitization by tubercle bacilli and by other mycobacteria in Ethiopian school-children. Eshetu Lema and Stanford, J. (A)	362
China, People's Republic of,	
30th anniversary of the founding of the Institute of Dermatology, CAMS celebrated. Ye, G.-Y. (N)	318
Experiences with phenazine dye, B628, in the treatment of leprosy in China. Li, F. T. (A)	670
Former IJL Editor returns to China. (N)	659
Institute of Dermatology, CAMS relocated. Ye, G.-Y. (N)	122
Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., <i>et al.</i> (O)	79
National conference on Propaganda and Education of Leprosy held in Nanjing. Ye, G.-Y. (N)	659
Understanding of leprosy in ancient China. Skinsnes, O. K. and Chang, P. H. C. (E)	289
Cholesterol,	
An <i>in vitro</i> test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of <i>Mycobacterium leprae</i> . Nair, I. and Mahadevan, P. R. (A)	671
Chromatography,	
Comparative study on the thin-layer chromatographic pattern of methyl mycolates of <i>M. leprae</i> and related species. Datta, A. K., <i>et al.</i> (O)	45
Rapid detection of mycobacterial contamination in batches of whole cells of purified <i>Mycobacterium leprae</i> by pyrolysis gas chromatography. Wieten, G., <i>et al.</i> (A)	348
Use of gas chromatography to differentiate <i>Mycobacterium leprae</i> from cultivable armadillo-derived mycobacteria, <i>M. avium/intracellulare</i> , and <i>M. lepraemurium</i> by analysis of secondary alcohols. Larsson, L., <i>et al.</i> (O)	441
Chromosomes,	
Chromosomal aberrations in cultures of skin fibroblasts of leprosy patients. Hackel, C. and Beiguelman, B. (O)	533
Clinical	
A retrospective study of leprosy in an industrial hospital. Ramanan, C., <i>et al.</i> (A)	692
Absence of triradium d on the palm of a leprosy patient. Gupta, C. M., <i>et al.</i> (A)	499
An analysis of leprosy incidence by patient age and the clinical form of the disease. Ferreira, J., <i>et al.</i> (A)	691
Arteriography in leprosy. Agrawal, B. R. and Agrawal, R. I. (A)	673
Clinical aspects. Jacobson, R. R. (A)	162
Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., <i>et al.</i> (A)	499
Electro-cardiographic changes in multibacillary leprosy. Agrawal, S. and Aggarwal, S. K. (A)	331
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. (A)	693
Hypercalcemia in leprosy. Ryzen, E. and Singer, F. R. (A)	675
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. (N)	319
NADH-Methemoglobin reductase and reticulocytosis. Caticha-Alfonso, O. (C)	483
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., <i>et al.</i> (A)	669
Some data on pharmacokinetics of dimociphon in leprosy (experimental and clinical investigation). Gnenjuk, T. S. (A)	494
Spontaneous healing in paucibacillary leprosy. Jesudasan, K. and Christian, M. (A)	499
The patient with sensory loss. Coleman, W. C. and Madrigal, D. R. (O)	255
The placenta in leprosy. Duncan, M. E., <i>et al.</i> (A)	336

Untreated Hansen's disease of the eye: a clinicopathological report. Robertson, I., <i>et al.</i> (A)	675
Value of pilocarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., <i>et al.</i> (A)	498
Clofazimine,	
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. (A)	677
Clofazimine and the eye: preliminary communication. Negrel, A. D., <i>et al.</i> (A)	330
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes <i>in vitro</i> . Anderson, R. (A)	327
Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Mathur, A., <i>et al.</i> (A)	670
Exfoliative dermatitis after clofazimine. Pavithran, K. (C)	645
<i>Lamprene (Clofazimine, B663) on Leprosy; Basic Information.</i> (N)	126
LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., <i>et al.</i> (A)	673
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., <i>et al.</i> (A)	330
Rapid, radiometric <i>in vitro</i> assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., <i>et al.</i> (A)	670
The pharmacology of intermittent clofazimine therapy in Hansen's disease. Morales, M. J., <i>et al.</i> (A)	166
Complement,	
Conversion of the C3 component of complement in sera of hanseniasis patients. Klie-mann, T. A. E., <i>et al.</i> (A)	142
Leprosy: altered complement receptors in disseminated disease. Tausk, F., <i>et al.</i> (A)	683
Reduced complement-mediated immune complex solubilization in leprosy patients. Ramanathan, V. D., <i>et al.</i> (A)	681
Control of leprosy,	
Analysis of leprosy control program in Pakistan. Pfau, R. (A)	512
Chemotherapy of Leprosy for Control Programs videotape available. (N)	126
Chemotherapy of leprosy—a tool for leprosy control (The Kellersberger Memorial Lecture, 1984). Levy, L. (A)	669
Comparative value of dapsone "spot test" and dapsone "tile test" in leprosy control programme. Naik, S. S. (A)	496
Diagnostic efficiency of paramedical workers involved in leprosy case detection. Kumar, A., <i>et al.</i> (A)	332
<i>Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group.</i> WHO Tech. Rpt. Ser. 716. (B)	491
. (N)	663
Leprosy case detection rates by age, sex and polar type under leprosy control conditions. de Vries, J. L. and Perry, B. H. (A)	355
Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., <i>et al.</i> (O)	79
Leprosy control in Sind. Pfau, R. (A)	358
Leprosy detection through non-survey techniques. Ganapati, R., <i>et al.</i> (A)	355
Patient compliance in leprosy control: a necessity in old and new regimens. Huikeshoven, H. (E)	474
Proceedings of the 5th International Workshop on Leprosy Control in Asia. Leprosy Control in Urban Community. (B)	323
Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy. Jesudasan, J. and Christian, M. (O)	19
Social factors and leprosy in Lamjung, west central Nepal: implication for disease control. Pearson, M. (A)	358
Strategy for leprosy control. Lagrange, P. H. and Stach, J. L. (E)	278
Surveillance in leprosy. Jesudasan, K. and Christian, M. (A)	692
Corticosteroids,	
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. (A)	677

- Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* (A) 679
- Corynebacteria,**
- Cell envelope architectures of leprosy-related corynebacteria, *Mycobacterium leprae*, and related organisms: a comparative study. Rastogi, N., *et al.* (A) 145
- Comparative properties of *Mycobacterium leprae* and leprosy-derived corynebacteria. Cocito, C. (A) 712
- Description of *Corynebacterium tuberculostearicum* sp. nov., a leprosy-derived corynebacterium. Brown, S., *et al.* (A) 343
- Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* (A) 343
- Occurrence of antigen BCG 60 in leprosy-derived corynebacteria and other coryneforms. Papa, F. P., *et al.* (A) 345
- Cultivation,**
- Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with *Mycobacterium leprae*. Portaels, F., *et al.* (A) 687
- Cultivation of *M. leprae* using perfluorocarbon beddings. Juscenko, A. A. and Irtuganova, O. A. (A) 507
- Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. (A) 345
- In vitro* cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. (A) 493
- Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. (A) 506
- Trials of culturing of *Mycobacterium leprae* using media enriched with thyroid hormones. Massalski, W., *et al.* (A) 145
- Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. aviun/intracellulare*, and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* (O) 441
- Cutaneous,**
- An electron microscopic study of the small cutaneous vessels in leprosy. Burchard, G.-D. and Bierther, M. (O) 70
- Cutaneous coccidioidomycosis simulating lepromatous leprosy. Hobbs, E. R. and Hempstead, R. W. (A) 332
- Cutaneous inoculation tuberculosis secondary to "jailhouse tattooing." Horney, D. A., *et al.* (A) 514
- Cutaneous *Mycobacterium szulgai* infection. Cross, G. M., *et al.* (A) 361
- Observations on local heat treatment for cutaneous leishmaniasis. Neva, F. A., *et al.* .. (A) 151
- Cycloheximide,**
- Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. (A) 345
- Cycloserine,**
- Activity of the combination of fludalanine and cycloserine against mycobacteria *in vitro*. Dickinson, J. M. and Mitchison, D. A. (A) 695
- Dapsone (DDS),**
- An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. (A) 167
- Chemical characterization of the dapsone binding site of lysozyme. Datta, G., *et al.* ... (O) 428
- Comparative value of dapsone "spot test" and dapsone "tile test" in leprosy control programme. Naik, S. S. (A) 496
- Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* (O) 378
- Dapsone and aplastic anemia. Foucauld, J., *et al.* (A) 327
- Dapsone resistance in patients attending Central Leprosy Teaching and Research Institute, Chengalpattu (South India). Bhatia, V. N., *et al.* (A) 327
- DDS-resistant leprosy. Neelan, P. N. and Reddy, B. N. (C) 115
- Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro*. Anderson, R. (A) 327

Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. (A)	608
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. (A)	329
Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., <i>et al.</i> (A)	672
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., <i>et al.</i> (O)	421
Norethisterone and ethinyl estradiol kinetics during dapsone therapy. Joshi, J. V., <i>et al.</i> (A)	328
Prevalence of secondary dapsone resistance in Nepal. Samuel, N. M., <i>et al.</i> (A)	497
Prevalence of secondary dapsone-resistant leprosy in Upper Volta. Pattyn, S. R., <i>et al.</i> (A)	330
Primary dapsone resistant leprosy in Nepal. Samuel, N. M., <i>et al.</i> (A)	497
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta-Palacios, J. J., <i>et al.</i> (A)	669
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., <i>et al.</i> (A)	669
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L. (A)	696
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. (O)	189
Response to Drs. Neelan and Reddy (DDS-resistant leprosy). Almeida, J. G. and Chacko, C. J. G. (C)	116
Role of dapsone in chemotherapy of leprosy—a comparison of responses to therapy in two cohorts in 1960s and 1970s. Reddy, B. N. and Neelan, P. N. (A)	497
Synergistic activity of dapsone and brodimoprim (a dihydrofolate inhibitor) against <i>Mycobacterium leprae</i> . Jagannathan, R. and Mahadevan, P. R. (A)	495
The dapsone syndrome. A case report. Gupta, C. M., <i>et al.</i> (A)	668
The neurotoxicity of dapsone. Daneshmend, T. K. (A)	494
Toxicity of prothionamide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A)	134
Urine test for monitoring regular self-administration of dapsone and its application. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A)	133
Vitamin E and dapsone-induced hemolysis. Kelly, J. W., <i>et al.</i> (A)	135
Deformity(ies),	
Deformities in leprosy patients attending urban leprosy clinic at Varanasi (India). Kaur, P. and Singh, G. (A)	694
Extensor pollicis brevis deviation graft operation in case of Z-deformity of the thumb in ulnar palsy—a preliminary report. Beine, A. (A)	693
<i>Management of Paralytic Deformities in Leprosy</i> . Andersen, J. G. and Brandsma, J. W. (B)	129
Dermatology,	
30th anniversary of the founding of the Institute of Dermatology, CAMS celebrated (China). Ye, G.-Y. (N)	318
Cyclosporine and murine allergic contact dermatitis. Rullan, P. P., <i>et al.</i> (A)	152
Differential diagnosis between leprosy and post-kala-azar dermal leishmaniasis. Ekambaram, V., <i>et al.</i> (A)	331
Exfoliative dermatitis after clofazimine. Pavithran, K. (C)	645
Fifth World Congress of Tropical Dermatology. Browne, S. G. (N)	125
<i>In vitro</i> studies on dermal granulomas of human leprosy—cellular characteristics. Narayanan, R. B., <i>et al.</i> (O)	39
Institute of Dermatology, CAMS relocated (China). Ye, G.-Y. (N)	122
Dermatoglyphics,	
Dermatoglyphics in leprosy (I. Finger patterns). Ghei, S. K., <i>et al.</i> (A)	498
Digital dermatoglyphics in leprosy patients with severe nerve damage. Baranov, Y. N., <i>et al.</i> (A)	498

- Distribution of blood groups and finger patterns in the families with leprosy patients.
Baranov, Y. N. and Podoplelov, I. I. (A) 498
- Results from cation and mass fingerprint analysis of single cells and from ATP measurements
of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* (O) 365
- Dharmendra,**
Evaluation of standard Dharmendra lepromin. Sengupta, U., *et al.* (A) 501
- DNA,**
Deoxyribonucleic acid relatedness among *Mycobacterium leprae*, *Mycobacterium leprae-
murium*, and selected bacteria by dot blot and spectrophotometric deoxyribonucleic
acid hybridization assays. Athwal, R. S., *et al.* (A) 342
- Dissection of *Mycobacterium tuberculosis* antigens using recombinant DNA. Young, R.
A., *et al.* (A) 699
- DNA from *Mycobacterium leprae*. David, H. L., *et al.* (A) 344
- DNA relatedness among *Mycobacterium leprae*, leprosy-derived bacteria, and estab-
lished mycobacterial species. Imaeda, T. and Portaels, F. (A) 170
- Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy pa-
tients' sera. Furukawa, F., *et al.* (C) 647
- Expression of cloned *Mycobacterium leprae* DNA in *Escherichia coli* K-12. Jacobs, W.
R., *et al.* (A) 170
- Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium
leprae*. Clark-Curtiss, J. E., *et al.* (A) 344
- Monoclonal antibodies and recombinant DNA technology: present and future uses in
leprosy and tuberculosis. Seckl, M. J. (E) 618
- Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential
new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* (A) 727
- The study of antibodies to DNA in the patients with complicated lepromatous leprosy.
Kuzina, Z. A. (A) 499
- Drug(s), see also specific drugs,**
A comparative evaluation of levamisole in leprosy. Sharma, L., *et al.* (A) 672
- A series of new antileprosy compounds derived from serotonin. Mester de Parajd, L.,
et al. (A) 670
- A study of the immunological effects of cimetidine in patients with lepromatous leprosy.
Brown, A. A., *et al.* (O) 559
- Activity of the combination of fludalanine and cycloserine against mycobacteria *in vitro*.
Dickinson, J. M. and Mitchison, D. A. (A) 695
- Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy
meeting, 10–11 October 1983. (N) 125
- An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensi-
tivity and resistance of *Mycobacterium leprae*. Nair, I. and Mahadevan, P. R. (A) 671
- Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and
Rajan, M. A. (A) 677
- Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide.
Evstratova, V. A., *et al.* (A) 494
- Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnen-
juk, T. S. (A) 494
- Drug interactions in combined antileprosy therapy. Loginov, V. K., *et al.* (A) 496
- Drug sensitivity testing of *M. leprae*. Grosset, J., *et al.* (C) 118
- Effect of antacids on oral absorption of rifampicin. Khalil, S. A. H., *et al.* (A) 669
- Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy.
Steffen, C. (A) 608
- Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clo-
fazimine from gastrointestinal tract. Mathur, A., *et al.* (A) 670
- Experimental thalidomide neuropathy: the morphological correlate of reduced conduc-
tion velocity. Schroder, J. M. and Matthiesen, T. (A) 672
- Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo*
lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* (A) 679
- Immunostimulatory effect of levamisole in borderline leprosy cases. Arora, S. K., *et al.*
. (A) 673

<i>In vitro</i> drug screening system using membrane alteration in macrophages by <i>Mycobacterium leprae</i> . Mankar, M. V., <i>et al.</i> (A)	507
Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., <i>et al.</i> (A)	672
Influence of levamisole on lymphocytes and <i>M. leprae</i> in mice. Ganguly, N. K., <i>et al.</i> (A)	689
LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., <i>et al.</i> (A)	673
Levamisole in cases of ENL. Arora, S. K., <i>et al.</i> (A)	668
Pattern of drug resistance in tuberculosis. Hardas, U. D. and Jayaraman, V. S. (A)	695
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta-Palacios, J. J., <i>et al.</i> (A)	669
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., <i>et al.</i> (A)	669
Rabbit sural nerve responses to chronic treatment with thalidomide and suplidimide. Schwab, B. W., <i>et al.</i> (A)	330
Rapid, radiometric <i>in vitro</i> assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., <i>et al.</i> (A)	670
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L. (A)	696
Response to Dr. Grosset, <i>et al.</i> (drug sensitivity testing of <i>M. leprae</i>). Almeida, J. G. and Chacko, C. J. G. (C)	120
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of <i>M. leprae</i> for drug sensitivity testing: a comparison. Seydel, U., <i>et al.</i> (O)	365
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae. Kurkcuoğlu, N., <i>et al.</i> (A)	696
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., <i>et al.</i> (A)	674
The search for new drugs for the treatment of leprosy. Hooper, M. (A)	494
The usage of liposomes for directed transport of drugs in leprosy (a preliminary report). Juscenko, A. A., <i>et al.</i> (A)	495
The use of " <i>M. lufu</i> " for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. (A)	494
Electron microscopy, see also Ultrastructure,	
An electron microscopic study of the small cutaneous vessels in leprosy. Burchard, G.-D. and Bierther, M. (O)	70
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. (O)	64
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with <i>M. leprae</i> . Fukunishi, Y. (O)	75
Electron microscopic findings of transverse fission of <i>M. leprae</i> by freeze-etching methods. Fukunishi, Y. (O)	247
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. (O)	577
Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. (O)	433
Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., <i>et al.</i> (A)	506
ELISA (enzyme-linked immunosorbent assay) tests,	
A specific glucose oxidase immunoenzyme stain for <i>Mycobacterium leprae</i> . Long, E. G., <i>et al.</i> (A)	176
An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., <i>et al.</i> (A)	149
Antibodies to <i>Mycobacterium leprae</i> detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., <i>et al.</i> (A)	354
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., <i>et al.</i> (O)	565

- Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* (A) 699
- Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* (A) 506
- ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas J. T., *et al.* (A) 180
- Enzyme immunoassay of serum β -2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* (A) 505
- Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* (A) 360
- Endocrine,**
- Endocrine profile and seminal plasma composition in Hansen's disease. Sultan Sheriff, D. (A) 138
- Enzyme(s),**
- Hydrolytic enzymes in macrophages from leprosy patients in presence of *Mycobacterium leprae*. Marolia, J. and Mahadevan, P. R. (A) 508
- Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., *et al.* (A) 151
- Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* (A) 348
- Eosinophilia,**
- Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. (A) 608
- Epidemiology,**
- An epidemiological study of leprosy among children in a rural area (India). Reddy, B. N. and Bansal, R. D. (A) 148
- Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. (A) 693
- Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group.* WHO Tech. Rpt. Ser. 716. (B) 491
..... (N) 663
- Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., *et al.* (O) 79
- Simulation of vaccination and resistance in leprosy using an epidemiometric model. Lechat, M. F., *et al.* (O) 461
- Erythema nodosum leprosum (ENL),**
- [Erythema nodosum leprosum as the first manifestation of leprosy]. Bano Aracil, M., *et al.* (A) 497
- Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., *et al.* (O) 211
- IgM antibodies against phenolic glycolipid I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* (A) 341
- In vitro* cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., *et al.* (A) 709
- Levamisole in cases of ENL. Arora, S. K., *et al.* (A) 668
- Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. (C) 313
- The use of colchicine in the management of type 2 lepra reaction (erythema nodosum leprosum). Stanley, J. N. A., *et al.* (A) 136
- Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* (A) 338
- Use of colchicine in the management of erythema nodosum leprosum (ENL). Sarojini, P. A. and Mshana, R. N. (A) 136

Ethiopia,

- Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. (O) 189
- Skin-test sensitization by tubercle bacilli and by other mycobacteria in Ethiopian school-children. Eshetu Lema and Stanford, J. (A) 362

Experimental leprosy,

- An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* (A) 691
- Animal models of leprosy. Meyers, W. M., *et al.* (A) 352
- Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., *et al.* (A) 351
- Experimental leprosy in nonhuman primates. Martin, L. N., *et al.* (A) 351
- Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* (A) 352
- Experimental leprosy in the mangabey (*Cercocebus atys atys*): necropsy findings. Baskin, G. B., *et al.* (A) 175
- Experimental leprosy in the mangabey (*Cercocebus atys*): necropsy findings. Baskin, G. B., *et al.* (O) 269
- Experimental leprosy in three species of monkeys. Wolf, R. H., *et al.* (A) 353
- Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* (A) 508
- Manifestation of experimental leprosy in the armadillo. Job, C. K., *et al.* (A) 350
- Protective properties of some bacterial antigens in experimental leprosy. Zajcev, R. A. and Umerov, G. G. (A) 506
- Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* (A) 169

Eye(s),

- 1984 Sixth Clayton Memorial Lecture: Leprosy and the Eye. (N) 127
- A survey of the eye complications of leprosy in South Korea. Courtright, P., *et al.* (A) 137
- Clofazimine and the eye: preliminary communication. Negrel, A. D., *et al.* (A) 330
- Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* (A) 176
- Intra-ocular tuberculosis associated with a penetrating injury. A case report. Murray, R. I. and Daya, H. (A) 697
- Leprosy and the eye: a review. fytche, T. J. and McDougall, A. C. (A) 674
- Ocular complications in patients with leprosy in Karigiri, South India. Her Hsin Tsai and Suryawanshi, N. (A) 674
- Ocular involvement from leprosy. Lamba, P. A. and Kumar, D. S. (A) 675
- The American Peace Corps Survey of the ocular complications of leprosy in South Korea. fytche, T. J. (A) 137
- Untreated Hansen's disease of the eye: a clinicopathological report. Robertson, I., *et al.* (A) 675

Face,

- Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* (A) 682

Family(ies),

- Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* (A) 163
- Antibodies to *Mycobacterium leprae* detected by enzyme-linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* (A) 354
- Distribution of blood groups and finger patterns in the families with leprosy patients. Baranov, Y. N. and Podoplelov, I. I. (A) 498

Fibronectin,

- Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* (A) 339

FLA-ABS,

- The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae*. Ji, B., *et al.* (A) 357

Foot,

- International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. (N) 319
Neuropathic ulcers of the foot. Lang-Stevenson, A. I., *et al.* (A) 694

Foot pad(s),

- Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* (O) 378
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* (C) 481
Studies on antimicrobial activity against *M. leprae* infections of the mouse foot pad. Gelber, R. H. (A) 171

Freeze-etching technique,

- Electron microscopic findings of transverse fission of *M. leprae* by freeze-etching methods. Fukunishi, Y. (O) 247
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* (A) 343

 γ -Interferon,

- Induction of γ -interferon with various mitogens in mice pretreated with *M. leprae-murium* and the effect of *in vivo* interferon production on the growth of *M. leprae-murium* in mice. Nomaguchi, H., *et al.* (A) 706

Genetic(s),

- Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* (A) 163
Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium in vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* (A) 353
Segregation and linkage analyses of 72 leprosy pedigrees. Haile, R. W. C., *et al.* (A) 356
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. (A) 719

Genome,

- Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium leprae*. Clark-Curtiss, J. E., *et al.* (A) 344

Germany,

- Malta Project completed. (N) 318

Granuloma(s),

- Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* (A) 503
Granuloma forming activity of mycolic acid-containing glycolipids in *Nocardia* and related taxa. Yano, I., *et al.* (A) 342
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* (A) 503
In vitro studies on dermal granulomas of human leprosy—cellular characteristics. Narayanan, R. B., *et al.* (O) 39
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy. Izaki, S., *et al.* (A) 350
Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* (A) 709
Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Cree, I. A., *et al.* (O) 582

Hand(s),

- Correction of intrinsic-minus hands associated with reversal of the transverse metacarpal arch. Palande, D. D. (A) 352
- Correction of ulnar claw hand by a loop of flexor digitorum superficialis motor for lumbrical replacement. Shah, A. (A) 359
- Extensor pollicis brevis deviation graft operation in case of Z-deformity of the thumb in ulner palsy—a preliminary report. Beine, A. (A) 693
- Hand function and leprosy. Cottler-Fox, M., *et al.* (A) 359
- International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. (N) 319
- Primary defects of the hand with intrinsic paralysis. Brandsma, J. W. and Andersen, J. G. (A) 359
- Silastic implant of the first dorsal interosseous space. Zacharia, A. G. and Gelber, R. H. (C) 643
- Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. (A) 513
- Weight appreciation in the hand in normal subjects and in patients with leprosy neuropathy. Raj, D. V., *et al.* (A) 675

Heiser Program, The,

- The Heiser Program for Research in Leprosy 1986. (N) 662

Hepatitis,

- A study of leprosy in relation with HBsAg. Jain, A. P., *et al.* (A) 332

Hepatotoxicity,

- Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* (A) 669
- Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., *et al.* (A) 134
- Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., *et al.* (O) 15

Histoid leprosy,

- Immunological status of histoid leprosy. Sehgal, V. N., *et al.* (A) 505

Histology,

- Enzyme immunoassay of serum β -2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* (A) 505
- Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., *et al.* (A) 683
- Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., *et al.* (O) 540
- Three histologic fixatives for the demonstration of *Mycobacterium leprae*. Jones, R. L. and McDougall, A. C. (A) 337

Histopathology,

- A sequential histopathological study of the lepromin reaction in leprosy patients. Mistry, N. F., *et al.* (A) 680
- Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* (A) 176

History,

- A brief history of Hansen's disease. Trautman, J. R. (A) 326
- Leprosy. Godal, T. (A) 141
- Leprosy. Reality and metaphor in literature. Prioleau, E. (A) 132
- Leprosy. The Moslem attitude. Mohammed, H. A. A. (A) 513
- Ma'i Ho'oka'awale—the Separating Sickness*. Gugelyk, T. and Bloombaum, M. (B) 129
- The leper in medieval Islamic society. Dols, M. W. (A) 132
- Tuberculosis and leprosy in antiquity; an interpretation. Manchester, K. (N) 326

HLA,

- Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., *et al.* (A) 118

- HLA class-II immune response genes and products in leprosy. de Vries, R. R. P., *et al.* (A) 502
- HLA-linked control of predisposition to lepromatous leprosy. Xu, K., *et al.* (O) 56
- HLA-linked control of predisposition to lepromatous leprosy. van Eden, W., *et al.* (A) 358
- Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* (A) 678
- Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schauf, V., *et al.* (A) 163
- Hydrocortisone,**
The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. (A) 500
- Hypersensitivity,**
Delayed-type hypersensitivity after immunization with ultrasonicated *Mycobacterium lepraemurium* in C3H and C57BL mice. Lovik, M., *et al.* (A) 351
- Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. (A) 329
- Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A) 502
- Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., *et al.* (A) 514
- Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* (A) 709
- ICRC bacilli,**
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A) 502
- IgG,**
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* (A) 360
- Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., *et al.* (O) 225
- IgM,**
Detection of IgM class on antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* (A) 175
- IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* (A) 341
- ILEP,**
ILEP Catalogue on Training, 1985. (N) 490
- XV General Assembly of ILEP (Italy). (N) 125
- IMMLEP,**
Phenolic glycolipid I now available in limited quantities (from IMMLEP Bank, London) (N) 319
- Immune complexes,**
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* (A) 137
- Isolation and analysis of circulating immune complexes in leprosy. Ramanathan, V. D., *et al.* (A) 144
- Reduced complement-mediated immune complex solubilization in leprosy patients. Ramanathan, V. D., *et al.* (A) 681
- The molecular basis of positive treponemal antibody, antinuclear antibody, and immune complex tests among Hansen's disease patients. Miller, R. A., *et al.* (A) 713
- Immune responses,**
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* (A) 720

An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., <i>et al.</i> (A)	149
Assessment of sensitin from <i>M. leprae</i> by cell-mediated and humoral immune reactions. Dyachina, M. N., <i>et al.</i> (A)	502
Cell-mediated immune response in intestinal tuberculosis. Bhargava, D. K., <i>et al.</i> (A)	360
Cell-mediated immunity in mice treated with <i>Mycobacterium leprae</i> or with macrophages harboring <i>M. leprae</i> . Ridet, P. R., <i>et al.</i> (A)	340
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to <i>Mycobacterium leprae</i> is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohaghehpour, N., <i>et al.</i> (A)	680
Effects of <i>Mycobacterium leprae</i> vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. (A)	174
HLA class-II immune response genes and products in leprosy. de Vries, R. R. P., <i>et al.</i> (A)	502
Hypothesis: possible idiotypic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., <i>et al.</i> (A)	140
Immune response in BALB/c mice following immunization with heat-killed <i>Mycobacterium lepraemurium</i> . Graham, L. and Navalkar, R. G. (A)	146
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by <i>in vivo</i> lepromin and <i>in vitro</i> CMI responses. Kundu, S. K., <i>et al.</i> (A)	679
<i>In situ</i> characterization of the cellular immune response in leprosy and leishmaniasis. Modlin, R. L., <i>et al.</i> (A)	181
<i>In vivo</i> responses to <i>Mycobacterium leprae</i> : antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., <i>et al.</i> (O)	385
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A)	502
Phenolic glycolipid 1 of <i>Mycobacterium leprae</i> causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., <i>et al.</i> (A)	139
Strain variation in murine immune response to the <i>M. leprae</i> glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., <i>et al.</i> (A)	721
The relation between cell-mediated immunity and blood groups in leprosy patients. Selezneva, S. P., <i>et al.</i> (A)	501
The role of lymphokines in cell-mediated immunity. Cohn, Z. A., <i>et al.</i> (A)	725
Immunoglobulin(s),	
Association between leprosy and immunoglobulin allotypes: Gm-A2m and Km frequencies in Vietnamese. de Lange, G., <i>et al.</i> (A)	355
Immunoglobulins in leprosy. Chiewsilp, P., <i>et al.</i> (O)	28
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., <i>et al.</i> (O)	225
Immunology,	
A study of the immunological effects of cimetidine in patients with lepromatous leprosy. Brown, A. A., <i>et al.</i> (O)	559
<i>An Overview of Immunological Aspects of Human Leprosy.</i> Saha, K. (B)	131
Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., <i>et al.</i> (A)	163
Hansen's disease as a research model. Kaplan, G. and Cohn, Z. (A)	337
Immunologic assessment of <i>Mycobacterium leprae</i> antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. (A)	173
Immunological status of histoid leprosy. Sehgal, V. N., <i>et al.</i> (A)	505
Immunological unresponsiveness in leprosy. Bloom, B. R. and Mehra, V. (A)	678
Immunology of leprosy. Bloom, B. R., <i>et al.</i> (A)	335
Immunoregulatory defects in leprosy. Watson, S. R. and Bullock, W. E. (A)	144
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., <i>et al.</i> (O)	421
Numerical taxonomic and immunologic comparison of 36 leprosy-derived mycobacterial strains and 17 members of the MAIS complex. Skinsnes, O. K., <i>et al.</i> (A)	167

<i>The Biology of the Mycobacteria. Vol. 2. Immunological and Environmental Aspects.</i>		
Ratledge, C. and Stanford, J.	(B)	664
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A.	(A)	503
Immunopharmacology,		
The immunopharmacology of antileprosy agents. Anderson, R.	(A)	133
Immunosuppression,		
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., <i>et al.</i>	(A)	146
Mechanism of immunosuppression in leprosy—macrophage membrane alterations. Salgame, P. R., <i>et al.</i>	(A)	144
Phagocytic and bactericidal activities of macrophages from <i>Mycobacterium leprae</i> -infected normal and immunosuppressed mice. Vaishnavi, C., <i>et al.</i>	(O)	233
The influence of immunosuppression and immunodeficiency on infections with leprosy and tuberculosis. Strickland, N. H.	(E)	86
Immunotherapy,		
Prospects for early diagnosis, immunotherapy, and vaccination for leprosy. Buchanan, T. M.	(A)	335
The value of using T and B lymphocytes for assessment of immunotherapy in leprosy patients. Selezneva, S. P.	(A)	505
India,		
1983–1984 Gandhi Memorial Leprosy Foundation report.	(N)	319
1984 ICMR awards.	(N)	659
1985 Magsaysay award to Baba Amte. Christian, M.	(N)	660
A study of knowledge, attitude and practice of leprosy among doctors of Bhopal, India. Sandhu, H. S., <i>et al.</i>	(A)	334
An epidemiological study of leprosy among children in a rural area. Reddy, B. N. and Bansal, R. D.	(A)	148
Central Leprosy Teaching and Research Institute, Chengalpattu, 1982 Annual Report.	(N)	123
Childhood leprosy and social response in South India. Berreman, J. M.	(A)	512
Community leaders' involvement in leprosy health education. Kumar, A., <i>et al.</i>	(A)	493
Dapsone resistance in patients attending Central Leprosy Teaching and Research Institute, Chengalpattu. Bhatia, V. N., <i>et al.</i>	(A)	327
Deformities in leprosy patients attending urban leprosy clinic at Varanasi. Kaur, P. and Singh, G.	(A)	694
Dr. B. R. Chatterjee awarded "Padma Shri." Christian, M.	(N)	660
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A.	(A)	693
Formation of Karnataka State Anti-Leprosy Council. Marshall, J. T.	(N)	319
Gynaecomastia in leprosy in three districts of Tamil Nadu. Roy, R. G., <i>et al.</i>	(A)	334
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985. Patil, K. M.	(N)	319
Involvement of medical students in leprosy through video films and books. Ganapati, R.	(N)	123
Multidrug therapy for multibacillary cases in Wardha District, Maharashtra. Nilakanta Rao, M. S. and Yellapurkar, M. V.	(A)	671
Nilayam report. Jagadisan, T. N.	(C)	658
Observations on the intrafamilial clustering of leprosy cases in Trivandrum City. Chidambaram Pillai, S., <i>et al.</i>	(A)	511
Ocular complications in patients with leprosy in Karigiri, South India. Her Hsin Tsai and Suryawanshi, N.	(A)	674
Padma Shri awarded to Dr. H. Srinivasan.	(N)	123
Schieffelin Leprosy Research and Training Center, Karigiri, 1985–1986 Course Schedule.	(N)	320
Second Erwin Stindl Memorial Oration given.	(N)	660
Socio-economic problems of leprosy patients and their relatives in Gujarat State. Kant, V. P.	(A)	511

Socio-environmental factors in relation to leprosy at Jaipur. Ojha, K. S., <i>et al.</i> (A)	512
State leprosy officers and regional directors hold conference. Christian, M. (N)	660
The Dr. Raghavendra Row Memorial Teaching Program in Leprosy—1985. Naik, S. S. (N)	490
The Macrophage in Leprosy proceedings available. Antia, N. H. (N)	660
Training workshop held. Christian, M. (N)	660
Treatment of leprosy in rural India as seen on a medical student elective. Riley, D. N. (A)	326
Video tapes and slides on leprosy now available. (N)	124
XIII Biennial Conference of the Indian Association of Leprologists held in Bombay. Pandya, S. S. (N)	123
Injection(s),	
Anti- <i>Mycobacterium leprae</i> antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., <i>et al.</i> (A)	336
Inoculation,	
Cutaneous inoculation tuberculosis secondary to "jailhouse tattooing." Horney, D. A., <i>et al.</i> (A)	514
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with <i>Mycobacterium lepraemurium</i> . Hoffenbach, A., <i>et al.</i> (A)	349
Influence of dose and route of <i>Mycobacterium lepraemurium</i> inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., <i>et al.</i> (A)	679
Inoculation leprosy subsequent to dog bite. A case report. Gupta, C. M., <i>et al.</i> (A)	499
Interleukin(s),	
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to <i>Mycobacterium leprae</i> is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohaghehpour, N., <i>et al.</i> (A)	680
Human recombinant interleukin-2 is mitogenic to human lymphocytes. Mookerjee, B. K. and Pauly, J. L. (A)	697
<i>In situ</i> identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., <i>et al.</i> (A)	503
<i>In vivo</i> responses to <i>Mycobacterium leprae</i> : antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., <i>et al.</i> (O)	385
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with <i>Mycobacterium lepraemurium</i> . Hoffenbach, A., <i>et al.</i> (A)	349
Influence of dose and route of <i>Mycobacterium lepraemurium</i> inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., <i>et al.</i> (A)	679
Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath, I., <i>et al.</i> (A)	339
Interleukin-2-induced T-cell response to <i>M. leprae</i> in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small <i>M. leprae</i> -reactive T-cell pool? Shankar, P., <i>et al.</i> (C)	649
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to <i>Mycobacterium leprae</i> . Haregewoin, A., <i>et al.</i> (A)	141
Serum soluble interleukin-2 receptors in leprosy patients. Tung, K. S. K., <i>et al.</i> (A)	719
INTERNATIONAL JOURNAL OF LEPROSY (IJL),	
Former IJL Editor returns to China. (N)	659
IJL instructions to authors. (N)	498
Reviewers for Volume 53. (—)	729
Statement of financial condition. (—)	731
Statement of ownership, management, and circulation. (—)	735
The 1984 JOURNAL—a continuing perspective. Hastings, R. C. (E)	101
International Leprosy Association (ILA),	
Officers and councillors. (—)	730

Iron,

- Diphenoloxidase of *Mycobacterium leprae* is not iron-dependent. Prabhakaran, K. and Harris, E. B. (A) 508

Isoenzyme(s),

- Isoenzyme patterns of mycobacteria. I. Factors influencing LDH isoenzymes of mycobacteria. Sharma, V. D., *et al.* (A) 688
- Isoenzymes of mycobacteria. II. Relevance of LDH zymograms in taxonomy and identification. Katoch, V. M., *et al.* (A) 686
- LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., *et al.* (A) 673

Italy,

- XV General Assembly of ILEP. (N) 125

Kellersberger Memorial Lecture, 1984,

- Chemotherapy of leprosy—a tool for leprosy control. Levy, L. (A) 669

Kidney(s),

- Associated hepatic and renal damages in lepromatous leprosy patients. Loginev, V. K. and Vishnevetsky, F. E. (A) 500
- Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., *et al.* (A) 499
- Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. (A) 340
- Renal functional status in leprosy. Kanwar, A. J., *et al.* (A) 332
- Renal lesions and other major findings in necropsies of 133 patients with leprosy. Date, A., *et al.* (O) 455
- Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Kar, H. K. and Roy, R. G. (A) 495
- Successful kidney transplantation in leprosy and transitory recurrence of the disease. Tervel, J. L., *et al.* (O) 410

Kinetics,

- Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. (A) 149
- Norethisterone and ethinyl estradiol kinetics during dapsone therapy, Joshi, J. V., *et al.* (A) 328

Korea,

- A survey of the eye complications of leprosy in South Korea. Courtright, P., *et al.* (A) 137
- Posthumous award for Erwin Stindl. (N) 659
- The American Peace Corps Survey of the ocular complications of leprosy in South Korea. ffytche, T. J. (A) 137

Lactic acid,

- The assessment of activity of leprosy process and effectiveness of antileprosy therapy by excess lactate in blood. Ryzhova, N. Y. (A) 501

Lamprène® (see Clofazimine),**Langerhans' cells,**

- Normal numbers of T6 positive epidermal Langerhans' cells across the leprosy spectrum. Narayanan, R. B., *et al.* (A) 143
- Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., *et al.* (A) 503

Leishmaniasis,

- Differential diagnosis between leprosy and post-kala-azar dermal leishmaniasis. Ekambaram, V., *et al.* (A) 331
- In situ* characterization of the cellular immune response in leprosy and leishmaniasis. Modlin, R. L., *et al.* (A) 181
- Leprosy and leishmaniasis. Berger, T. G. (A) 148
- Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Weldon, J. S., *et al.* (A) 153
- Observations on local heat treatment for cutaneous leishmaniasis. Neva, F. A., *et al.* . . (A) 151

Specific suppression of responses to <i>Leishmania tropica</i> by a cloned T-cell line. Liew, F. Y. (A)	362
Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. Reed, S. G., <i>et al.</i> (A)	152
Lepromatous leprosy,	
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., <i>et al.</i> (A)	349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., <i>et al.</i> (A)	172
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., <i>et al.</i> (O)	554
A study of the immunological effects of cimetidine in patients with lepromatous leprosy. Brown, A. A., <i>et al.</i> (O)	559
Adrenal cortical function and reserve in lepromatous leprosy. Durairaj, V., <i>et al.</i> (A)	498
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. (O)	64
An unusual case of untreated polar lepromatous leprosy associated with rare <i>M. leprae</i> . Gelber, R. H. (C)	311
Anti- <i>Mycobacterium leprae</i> antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., <i>et al.</i> (A)	144
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., <i>et al.</i> (A)	724
Associated hepatic and renal damages in lepromatous leprosy patients. Loginov, V. K. and Vishnevetsky, F. E. (A)	500
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., <i>et al.</i> (A)	148
Cardiac dysautonomia in lepromatous leprosy. Kale, H. D., <i>et al.</i> (A)	332
Cutaneous coccidioidomycosis simulating lepromatous leprosy. Hobbs, E. R. and Hempstead, R. W. (A)	332
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to <i>Mycobacterium leprae</i> is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohaghehpour, N., <i>et al.</i> (A)	680
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., <i>et al.</i> (A)	504
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., <i>et al.</i> (A)	137
Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy patients' sera. Furukawa, F., <i>et al.</i> (C)	647
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., <i>et al.</i> (C)	113
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. (O)	577
Evidence for the presence of <i>M. leprae</i> reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., <i>et al.</i> (A)	340
Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. (O)	546
Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., <i>et al.</i> (A)	176
HLA-linked control of predisposition to lepromatous leprosy. Xu, K., <i>et al.</i> (O)	56
HLA-linked control of predisposition to lepromatous leprosy. von Eden, W., <i>et al.</i> (A)	358
Hypothesis: possible idiotypic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., <i>et al.</i> (A)	140
Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., <i>et al.</i> (O)	218

Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath, I., <i>et al.</i> (A)	339
Interleukin-2-induced T-cell response to <i>M. leprae</i> in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small <i>M. leprae</i> -reactive T-cell pool? Shankar, P., <i>et al.</i> (C)	649
Isolation of phenolic glycolipid-I from human lepromatous nodules. Vemuri, N., <i>et al.</i> (C)	487
Lepromatous leprosy complicated with systemic lupus erythematosus. Ohkawa, S., <i>et al.</i> (A)	675
Mechanism of unresponsiveness in lepromatous leprosy. Mehra, V., <i>et al.</i> (A)	180
Phosphatidyl inositol mannosides in lepromatous leprosy nodules. Khande, L., <i>et al.</i> . . (A)	142
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., <i>et al.</i> (A)	678
Reduced expression of C3b receptors on erythrocytes from patients with lepromatous leprosy. Tausk, F., <i>et al.</i> (A)	184
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, C. (O)	189
Relationship between the loss of maxillary anterior alveolar bone and the duration of untreated lepromatous leprosy in Malaysia. Seang Hoo Nah, <i>et al.</i> (A)	501
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to <i>Mycobacterium leprae</i> . Haregewoin, A., <i>et al.</i> (A)	141
Thalidomide enhances defective monocyte function in lepromatous leprosy. Nielsen, H. and Bennike, T. (A)	135
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. (A)	719
The changes in upper respiratory organs in the discharged patients with "burnt out" lepromatous leprosy. Kaipbergenov, U. K. (A)	499
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A. (A)	503
The <i>in vitro</i> dynamics of cyclic adenosine monophosphate levels in lymphocytes from lepromatous leprosy patients (the first report). Balybin, E. S. (A)	501
The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. (A)	500
The spectrum of <i>in vitro</i> T-cell responsiveness in lepromatous leprosy. Kaplan, G., <i>et al.</i> (A)	708
The study of antibodies to DNA in the patients with complicated lepromatous leprosy. Kuzina, Z. A. (A)	499
Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., <i>et al.</i> . . (A)	682
Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., <i>et al.</i> (O)	373
Lepromin,	
A sequential histopathological study of the lepromin reaction in leprosy patients. Mistry, N. F., <i>et al.</i> (A)	680
Anti- <i>Mycobacterium leprae</i> antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., <i>et al.</i> (A)	336
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., <i>et al.</i> (C)	113
Evaluation of standard Dharmendra lepromin. Sengupta, U., <i>et al.</i> (A)	501
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by <i>in vivo</i> lepromin and <i>in vitro</i> CMI responses. Kundu, S. K., <i>et al.</i> (A)	679
<i>In vitro</i> cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., <i>et al.</i> (A)	709
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	707
The cell interaction in lepromin test. Ibraimov, M. (A)	502

Lesions,

- A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* (O) 554
- Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* (A) 504
- Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. (O) 75
- Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* (A) 339
- First lesion in experimental armadillo leprosy. Job, C. K., *et al.* (A) 690
- Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., *et al.* (A) 683
- In vivo* responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* (O) 385
- Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* (A) 707
- Lysozyme as a measure of cellular dynamics in the lesions of leprosy. Ridley, M. J., *et al.* (A) 341
- Persistence of Langhans' giant cells in rapidly downgrading leprosy lesions. Lyons, N. F., *et al.* (C) 114
- Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* (A) 678
- Renal lesions and other major findings in necropsies of 133 patients with leprosy. Date, A., *et al.* (O) 455
- Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* ... (A) 682

Leukocytes,

- Enhancement by clofazimine and inhibition by dapson of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro*. Anderson, R. (A) 327
- The effect of *Mycobacterium leprae* on PHA- and PPD-induced inhibition of leukocyte migration in leprosy patients. Dharma Rao, T., *et al.* (A) 679

Levamisole,

- A comparative evaluation of levamisole in leprosy. Sharma, L., *et al.* (A) 672
- Effect of levamisole on bacterial index in BL and LL leprosy. Bera, D. K. and Sen, P. C. (O) 198
- Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* (C) 113
- Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* (A) 679
- Immunostimulatory effect of levamisole in borderline leprosy cases. Arora, S. K., *et al.* (A) 673
- Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* (A) 689
- Levamisole in cases of ENL. Arora, S. K., *et al.* (A) 668

Lipid(s),

- Characterization of *Mycobacterium leprae* by lipid analysis. Minnikin, D. E., *et al.* ... (A) 345
- Lipids as taxonomic markers for bacteria derived from leprosy infections. Asselineau, C., *et al.* (A) 342
- Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of *Mycobacterium tuberculosis*. Goren, M. B., *et al.* (A) 150
- The free lipids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., *et al.* (A) 686

Liposome,

- The usage of liposomes for directed transport of drugs in leprosy (a preliminary report). Juscenko, A. A., *et al.* (A) 495
- Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. Reed, S. G., *et al.* (A) 152

Lymphocyte(s),

- An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. (O) 64
- Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., *et al.* (A) 351
- Evidence for the presence of *M. leprae* reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., *et al.* (A) 340
- Human recombinant interleukin-2 is mitogenic to human lymphocytes. Mookerjee, B. K. and Pauly, J. L. (A) 697
- Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to *Mycobacterium leprae*. Douglas-Jones, A. G. and Watson, J. D. (O) 412
- Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* (A) 146
- In vitro* lymphocyte stimulating ability of cell components of *Mycobacterium leprae*. Khandke, L., *et al.* (A) 337
- Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* (A) 689
- Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* (A) 707
- Lymphocyte suppression in leprosy induced by unique *M. leprae* glycolipid. Mehra, V., *et al.* (A) 680
- Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* (A) 169
- Thalidomide induces imbalances in T lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* (A) 502
- The *in vitro* dynamics of cyclic adenosine monophosphate levels in lymphocytes from lepromatous leprosy patients (the first report). Balybin, E. S. (A) 501
- The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. (A) 500
- The value of using T and B lymphocytes for assessment of immunotherapy in leprosy patients. Selezneva, S. P. (A) 505
- Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* (A) 338

Lysozyme,

- Chemical characterization of the dapsone binding site of lysozyme. Datta, G., *et al.* . . . (O) 428
- Lysozyme as a measure of cellular dynamics in the lesions of leprosy. Ridley, M. J., *et al.* (A) 341
- Muramidase (lysozyme) findings in sural and radial nerve biopsies in leprosy patients after varying periods of treatment. Haimanot, R. T., *et al.* (O) 238

Macrophage(s),

- Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. (A) 688
- An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. (O) 64
- An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae*. Nair, I. and Mahadevan, P. R. (A) 671
- Cell-mediated immunity in mice treated with *Mycobacterium leprae* or with macrophages harboring *M. leprae*. Ridel, P. R., *et al.* (A) 340
- Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* (O) 378
- Exchange of material between the extracellular medium and macrophage phagosomes containing different species of bacteria including mycobacteria. de Chastellier, C. and Lang, T. (A) 336
- Functionality of secondary lysosomes in murine resident peritoneal macrophages. Goren, M. B., *et al.* (A) 726

Genetic resistance of mice to persistent infection with <i>Mycobacterium lepraemurium</i> <i>in vitro</i> : association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., <i>et al.</i> (A)	353
Hydrolytic enzymes in macrophages from leprosy patients in presence of <i>Mycobacterium leprae</i> . Marolia, J. and Mahadevan, P. R. (A)	508
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., <i>et al.</i> (A)	146
<i>In vitro</i> drug screening system using membrane alteration in macrophages by <i>Mycobacterium leprae</i> . Mankar, M. V., <i>et al.</i> (A)	507
Macrophage activation in mice infected with <i>Mycobacterium lepraemurium</i> . Brett, S. J. (A)	349
Macrophage activity in <i>Mycobacterium leprae</i> infection. Sharp, A. K. and Banerjee, D. K. (A)	341
Macrophage interaction with mycobacteria including <i>M. leprae</i> . Ryter, A., <i>et al.</i> (A)	346
Mechanism of immunosuppression in leprosy—macrophage membrane alterations. Salgame, P. R., <i>et al.</i> (A)	144
Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. (A)	506
Phagocytic and bactericidal activities of macrophages from <i>Mycobacterium leprae</i> -infected normal and immunosuppressed mice. Vaishnavi, C., <i>et al.</i> (D)	233
Susceptibility of <i>Mycobacterium leprae</i> to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., <i>et al.</i> (A)	342
“The Macrophage in Leprosy” proceedings available. Antia, N. H. (N)	660
Malaysia,	
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. (A)	329
<i>Leprosy in Malaysia; Past, Present and Future</i> . Joshua-Raghavar, A. (B)	323
Relationship between the loss of maxillary anterior alveolar bone and the duration of untreated lepromatous leprosy in Malaysia. Seang Hoo Nah, <i>et al.</i> (A)	501
Metabolism,	
Alternate radiolabeled markers for detecting metabolic activity of <i>Mycobacterium leprae</i> residing in murine macrophages. Prasad, H. K. and Hastings, R. C. (A)	688
An <i>in vitro</i> test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of <i>Mycobacterium leprae</i> . Nair, I. and Mahadevan, P. R. (A)	671
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., <i>et al.</i> (A)	330
Mexico,	
Fifth World Congress of Tropical Dermatology. Browne, S. G. (N)	125
Mice,	
A dual effect of tilorone on multiplication of <i>Mycobacterium leprae</i> in mice. Levy, L. and Aizer, F. (A)	350
An experimental study of the antileprosy activity of a series of thioamides in the mouse. Shepard, C. C., <i>et al.</i> (O)	587
Antibody response to phenolic glycolipid I in inbred mice immunized with <i>Mycobacterium leprae</i> . Teuscher, C., <i>et al.</i> (A)	683
Cell-mediated immunity in mice treated with <i>Mycobacterium leprae</i> or with macrophages harboring <i>M. leprae</i> . Ridel, P. R., <i>et al.</i> (A)	340
Delayed-type hypersensitivity after immunization with ultrasonicated <i>Mycobacterium lepraemurium</i> in C3H and C57BL mice. Lovik, M., <i>et al.</i> (A)	351
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., <i>et al.</i> (A)	165
Efficacy of <i>Mycobacterium bovis</i> BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. (A)	697
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with <i>Mycobacterium leprae</i> . Sebille, A., <i>et al.</i> (C)	481
Experimental mycobacterial infections of CBA/N mice. Levy, L., <i>et al.</i> (A)	690
Genetic resistance of mice to persistent infection with <i>Mycobacterium lepraemurium</i> <i>in</i>	

- vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* (A) 353
- H-2-linked genes which modify resistance of C57BL/10 mice to subcutaneous infection with *Mycobacterium lepraemurium*. Curtis, J., *et al.* (A) 146
- Immune response in BALB/c mice following immunization with heat-killed *Mycobacterium lepraemurium*. Graham, L. and Navalkar, R. G. (A) 146
- Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A) 502
- Induction of gamma-interferon with various mitogens in mice pretreated with *M. lepraemurium* and the effect of *in vivo* interferon production on the growth of *M. lepraemurium* in mice. Nomaguchi, H., *et al.* (A) 706
- Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* (A) 349
- Influence of dose and route of *Mycobacterium lepraemurium* inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., *et al.* (A) 679
- Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* (A) 689
- Macrophage activation in mice infected with *Mycobacterium lepraemurium*. Brett, S. J. (A) 349
- Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., *et al.* (O) 421
- Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* (O) 233
- Phenolic glycolipid 1 of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., *et al.* (A) 139
- Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. (A) 698
- Serum enzymatic changes following infection of mice with *Mycobacterium lepraemurium*. Rojas-Espinosa, O., *et al.* (O) 258
- Strain variation of lymphokine production and specific antibody secretion in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* (A) 510
- Susceptibility of *Mycobacterium leprae* to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., *et al.* (A) 342
- Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* (A) 348
- T-cell responsiveness in *Mycobacterium lepraemurium* infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J. (A) 349
- The bactericidal activity of various aminoglycoside antibiotics against *Mycobacterium leprae* in mice. Gelber, R. H., *et al.* (A) 328
- Trophic changes and extensive dissemination in normal mice with human *Mycobacterium leprae*. Vaishnavi, C., *et al.* (A) 510
- Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Mackett, M., *et al.* (A) 353
- Mice, nude,**
- Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* (A) 720
- An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. (A) 167
- Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. (O) 75
- Experimental infection with *Mycobacterium kansasii* in athymic nude mice. Kubin, M., *et al.* (A) 362
- Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* (A) 352
- Mycobacterium lepraemurium* infection of nude athymic (nu/nu) mice. Lefford, M. J. (A) 690

The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y.	(A)	719
Microscopy,		
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from <i>M. leprae</i> . Samuel, N. M., <i>et al.</i>	(O)	395
Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., <i>et al.</i>	(A)	506
Mitsuda reaction,		
An <i>in situ</i> immunohistological study of Mitsuda reactions. Dugan, E., <i>et al.</i>	(O)	404
Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., <i>et al.</i>	(O)	540
Phenolic glycolipid-I: an immunogen for a Mitsuda response. Job, C. K., <i>et al.</i>	(A)	179
Monkey(s),		
Animal models of leprosy. Meyers, W. M., <i>et al.</i>	(A)	352
Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., <i>et al.</i>	(A)	351
Experimental leprosy in nonhuman primates. Martin, L. N., <i>et al.</i>	(A)	351
Experimental leprosy in the mangabey (<i>Cercocebus atys atys</i>): necropsy findings. Baskin, G. B., <i>et al.</i>	(A)	175
Experimental leprosy in the mangabey (<i>Cercocebus atys</i>): necropsy findings. Baskin, G. B., <i>et al.</i>	(O)	269
Experimental leprosy in three species of monkeys. Wolf, R. H., <i>et al.</i>	(A)	353
Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., <i>et al.</i>	(A)	176
Leprosy in a mangabey monkey—naturally acquired infection. Meyers, W. M., <i>et al.</i>	(O)	1
Leprosy in sub-human primates: potential risk for transfer of <i>M. leprae</i> to humans. Hagstad, H. V.	(A)	147
Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (<i>Cercocebus atys</i>). Martin, L. N., <i>et al.</i>	(A)	169
Monoclonal antibodies,		
A monoclonal antibody against <i>Mycobacterium lepraemurium</i> which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A.	(A)	138
Affinity purification of a 65,000 dalton protein of <i>Mycobacterium gordonae</i> using a monoclonal antibody which recognizes a shared epitope on the homologous protein of <i>Mycobacterium leprae</i> . Gillis, T. P.	(A)	718
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthews, R. C., <i>et al.</i>	(A)	503
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for <i>Mycobacterium leprae</i> . Gillis, T. P., <i>et al.</i>	(A)	178
Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., <i>et al.</i>	(A)	699
Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., <i>et al.</i>	(A)	339
Human monoclonal antibodies against <i>Mycobacterium leprae</i> . Atlaw, T., <i>et al.</i>	(A)	677
<i>In situ</i> identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., <i>et al.</i>	(A)	503
Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J.	(E)	618
Monoclonal antibodies to a 28,000 mol. wt protein antigen of <i>Mycobacterium leprae</i> . Young, D. B., <i>et al.</i>	(A)	684
Production and characterization of monoclonal antibodies to <i>Mycobacterium tuberculosis</i> . Kolk, A. H. J., <i>et al.</i>	(A)	338
Production of human monoclonal antibodies to <i>Mycobacterium leprae</i> . Mohaghehpour, N., <i>et al.</i>	(A)	178

- Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. (A) 682
- Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., *et al.* (A) 363
- Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* (O) 33
- Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. (A) 715
- Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* (O) 33
- Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. (A) 715
- Mononuclear cells,**
- Activation of human monocytes in leprosy. Ohkawa, S. (A) 681
- Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* (A) 503
- Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. (A) 149
- Morphology,**
- Correlation viability/morphology in *Mycobacterium leprae*. Silva, M. T., *et al.* (A) 347
- Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. (A) 672
- Morphological changes induced by β -lactum antibiotics in *Mycobacterium avium-intracellulare* complex. Mizuguchi, Y., *et al.* (A) 696
- Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. (A) 506
- Multidrug therapy (MDT),**
- Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* (A) 669
- Leprosy treatment in Nepal with multidrug regimens. Birch, M. C. (A) 133
- Managerial implications of multidrug therapy. Askew, A. D. (A) 668
- Multidrug regime in management of leprosy. Paradkar, S., *et al.* (A) 496
- Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. (A) 329
- Multidrug therapy for multibacillary cases in Wardha District, Maharashtra, India. Nilakanta Rao, M. S. and Yellapurkar, M. V. (A) 671
- Multidrug treatment of leprosy—practical application in Nepal. Samuel, N. M., *et al.* . . . (A) 136
- WHO meeting on multidrug therapy. (N) 126
- Murine,**
- Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. (A) 688
- Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. (A) 348
- Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. (O) 433
- Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to *Mycobacterium leprae*. Douglas-Jones, A. G. and Watson, J. D. (O) 412
- Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* (A) 146
- Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy. Izaki, S., *et al.* (A) 350
- Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* (A) 709
- Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* (A) 348

Mycobacteria,

Activity of the combination of fludalanine and cycloserine against mycobacteria <i>in vitro</i> . Dickinson, J. M. and Mitchison, D. A. (A)	695
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., <i>et al.</i> (A)	503
Concentration-dependent effects of mycobacteria on the stimulation of murine T-cell clones. Kingston, A. E. and Colston, M. J. (A)	337
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	687
Cytochemical characterization of mycobacterial outer surfaces. Picard, B., <i>et al.</i> (A)	346
DNA relatedness among <i>Mycobacterium leprae</i> , leprosy-derived bacteria, and estab- lished mycobacterial species. Imaeda, T. and Portaels, F. (A)	170
Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Smith, D., <i>et al.</i> (A)	363
Efficacy of <i>Mycobacterium bovis</i> BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. (A)	697
Exchange of material between the extracellular medium and macrophage phagosomes containing different species of bacteria including mycobacteria. de Chastellier, C. and Lang, T. (A)	336
Experimental mycobacterial infections of CBA/N mice. Levy, L., <i>et al.</i> (A)	690
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., <i>et al.</i> (A)	343
Further observations on the mycobacteriophage D29—mycobacterial interactions. Da- vid, H. L., <i>et al.</i> (A)	344
Inhibition of mycobacteria by garlic extract (<i>Allium sativum</i>). Delaha, E. C. and Ga- ragusi, V. F. (A)	695
Intracellular multiplication of leprosy-derived mycobacteria in Schwann cells of dorsal root ganglion cultures. Mukherjee, R. and Antia, N. H. (A)	687
Isoenzyme patterns of mycobacteria. I. Factors influencing LDH isoenzymes of my- cobacteria. Sharma, V. D., <i>et al.</i> (A)	688
Isoenzymes of mycobacteria. II. Relevance of LDH zymograms in taxonomy and iden- tification. Katoch, V. M., <i>et al.</i> (A)	686
Isolation of mycobacterial phage from the laboratory strain <i>Mycobacterium lepraemu- rium</i> "Douglas." Sula, L., <i>et al.</i> (A)	509
Lytic potency against various mycobacterial strains of the phage isolated from <i>Myco- bacterium lepraemurium</i> "Douglas." Sula, L. and Sulova, J. (A)	509
Macrophage interaction with mycobacteria including <i>M. leprae</i> . Ryter, A., <i>et al.</i> (A)	346
New-found glycolipid antigens of mycobacteria. Brennan, P. J. (A)	343
Numerical taxonomic and immunologic comparison of 36 leprosy-derived mycobac- terial strains and 17 members of the MAIS complex. Skinsnes, O. K., <i>et al.</i> (A)	167
Presence of "difficult-to-grow" mycobacteria in armadillos. Dhople, A. M., <i>et al.</i> (A)	166
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. (A)	698
Rapid detection of mycobacterial contamination in batches of whole cells of purified <i>Mycobacterium leprae</i> by pyrolysis gas chromatography. Wieten, G., <i>et al.</i> (A)	348
Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., <i>et al.</i> (A)	698
Skin-test sensitisation by tubercle bacilli and by other mycobacteria in Ethiopian school- children. Eshetu Lema and Stanford, J. (A)	362
<i>The Biology of the Mycobacteria. Vol. 2. Immunological and Environmental Aspects.</i> Ratledge, C. and Stanford, J. (B)	664
Use of gas chromatography to differentiate <i>Mycobacterium leprae</i> from cultivable ar- madillo-derived mycobacteria, <i>M. avium/intracellulare</i> , and <i>M. lepraemurium</i> by analysis of secondary alcohols. Larsson, L., <i>et al.</i> (O)	441
<i>Mycobacterium aurum,</i>	
Antibacterial action of colistin (polymyxin E) against <i>Mycobacterium aurum</i> . David, H. L. and Rastogi, N. (A)	685

Mycobacterium avium,

- Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. (A) 340

Mycobacterium avium-intracellulare,

- Intra- and extracellular susceptibility of *Mycobacterium avium-intracellulare* complex to aminoglycoside antibiotics. Nozawa, R. T., *et al.* (A) 152
- Morphological changes induced by β -lactam antibiotics in *Mycobacterium avium-intracellulare* complex. Mizuguchi, Y., *et al.* (A) 696
- Susceptibility of intra- and extracellular *Mycobacterium avium-intracellulare* to cephem antibiotics. Nozawa, R. T., *et al.* (A) 363
- Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare*, and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* (O) 441

Mycobacterium bovis,

- Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. (A) 149
- Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. (A) 697

Mycobacterium chelonae,

- In vitro* susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonae* to cefmetazole. Casal, M. J., *et al.* (A) 361
- Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis*, *M. leprae*, *M. ulcerans*, *M. chelonae* (abscessus), and *M. kansasii*. Wear, D. J., *et al.* (A) 684

Mycobacterium fortuitum,

- In vitro* susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonae* to cefmetazole. Casal, M. J., *et al.* (A) 361

Mycobacterium gordonae,

- Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae*. Gillis, T. P. (A) 718
- Quantitative comparison of the mycolic and fatty acid compositions of *Mycobacterium leprae* and *M. gordonae*. Minnikin, D. E., *et al.* (A) 687

Mycobacterium kansasii,

- Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis*, *M. leprae*, *M. ulcerans*, *M. chelonae* (abscessus), and *M. kansasii*. Wear, D. J., *et al.* (A) 684

Mycobacterium leprae,

- A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. (A) 506
- A dual effect of tilorone on multiplication of *Mycobacterium leprae* in mice. Levy, L. and Aizer, F. (A) 350
- A specific glucose oxidase immunoenzyme stain for *Mycobacterium leprae*. Long, E. G., *et al.* (A) 176
- Absence of mycobactin in *Mycobacterium leprae*; probably a microbe dependent microorganism. Implications. Kato, L. (A) 686
- Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* (A) 720
- Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae*. Gillis, T. P. (A) 718
- Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. (A) 688
- An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. (A) 167

An attempt to infect turtles (<i>Kinosternon leucostomum</i>) with <i>Mycobacterium leprae</i> and <i>M. lepraemurium</i> . Rojas-Espinosa, O., <i>et al.</i> (A)	691
An <i>in vitro</i> test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of <i>Mycobacterium leprae</i> . Nair, I. and Mahadevan, P. R. (A)	671
An unusual case of untreated polar lepromatous leprosy associated with rare <i>M. leprae</i> . Gelber, R. H. (C)	311
Antibodies to <i>Mycobacterium leprae</i> detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., <i>et al.</i> (A)	354
Antibody response to phenolic glycolipid I in inbred mice immunized with <i>Mycobacterium leprae</i> . Teuscher, C., <i>et al.</i> (A)	683
Anti- <i>Mycobacterium leprae</i> antibodies in urine from lepromatous patients examined by cross immunoelectrophoresis and radioimmunoassay. Olcén, P., <i>et al.</i> (A)	144
Anti- <i>Mycobacterium leprae</i> antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., <i>et al.</i> (A)	336
Assessment of sensitin from <i>M. leprae</i> by cell-mediated and humoral immune reactions. Dyachina, M. N., <i>et al.</i> (A)	502
Biochemical alterations in the serum of armadillos (<i>Dasypus novemcinctus</i>) infected with <i>Mycobacterium leprae</i> . A preliminary report. Rojas-Espinosa, O., <i>et al.</i> (O)	262
Cell envelope architectures of leprosy-related corynebacteria, <i>Mycobacterium leprae</i> , and related organisms: a comparative study. Rastogi, N., <i>et al.</i> (A)	145
Cell-mediated immunity in mice treated with <i>Mycobacterium leprae</i> or with macrophages harboring <i>M. leprae</i> . Ridel, P. R., <i>et al.</i> (A)	340
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for <i>Mycobacterium leprae</i> . Gillis, T. P., <i>et al.</i> (A)	178
Characterization of <i>Mycobacterium leprae</i> by lipid analysis. Minnikin, D. E., <i>et al.</i> (A)	345
Comparative properties of <i>Mycobacterium leprae</i> and leprosy-derived corynebacteria. Cocito, C. (A)	712
Comparative study on the thin-layer chromatographic pattern of methyl mycolates of <i>M. leprae</i> and related species. Datta, A. K., <i>et al.</i> (O)	45
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of <i>Mycobacterium leprae</i> sensitivity/resistance to dapsone. Sathish, M., <i>et al.</i> (O)	378
Correlation viability/morphology in <i>Mycobacterium leprae</i> . Silva, M. T., <i>et al.</i> (A)	347
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	687
Cultivation of <i>M. leprae</i> using perfluorocarbon beddings. Juscenko, A. A. and Irtuganova, O. A. (A)	507
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to <i>Mycobacterium leprae</i> is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., <i>et al.</i> (A)	680
Deoxyribonucleic acid relatedness among <i>Mycobacterium leprae</i> , <i>Mycobacterium lepraemurium</i> , and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., <i>et al.</i> (A)	342
Detection of an antigen (MY4) common to <i>M. tuberculosis</i> and <i>M. leprae</i> by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. (A)	681
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	175
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti- <i>M. leprae</i> antibodies. Sukhenko, L. T., <i>et al.</i> (A)	506
Diphenoloxidase of <i>Mycobacterium leprae</i> is not iron-dependent. Prabhakaran, K. and Harris, E. B. (A)	508
Distribution of <i>Mycobacterium leprae</i> in circular counting films. Humber, D. P. (C)	656
Distribution of <i>Mycobacterium leprae</i> in the circles of counting slides. Shepard, C. C. and Levy, L. (C)	653
DNA from <i>Mycobacterium leprae</i> . David, H. L., <i>et al.</i> (A)	344
DNA relatedness among <i>Mycobacterium leprae</i> , leprosy-derived bacteria, and established mycobacterial species. Imaeda, T. and Portaels, F. (A)	170
Drug sensitivity testing of <i>M. leprae</i> . Grosset, J., <i>et al.</i> (C)	118

Effects of <i>Mycobacterium leprae</i> vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. . . . (A)	174
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with <i>M. leprae</i> . Fukunishi, Y. (O)	75
Electron microscopic findings of transverse fission of <i>M. leprae</i> by freeze-etching methods. Fukunishi, Y. (O)	247
ELISA evaluation of phenolic glycolipid-I (PGI) and whole <i>M. leprae</i> with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., et al. (A)	180
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with <i>Mycobacterium leprae</i> . Sebille, A., et al. (C)	481
Evidence for the presence of <i>M. leprae</i> reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., et al. (A)	340
Expression of cloned <i>Mycobacterium leprae</i> DNA in <i>Escherichia coli</i> K-12. Jacobs, W. R., et al. (A)	170
Fatty acids in <i>M. leprae</i> purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., et al. (A)	508
Fixation of <i>Mycobacterium leprae</i> in unstained smears prior to shipment or storage: evaluation of formaldehyde using <i>Mycobacterium tuberculosis</i> as indicator of efficacy. Allen, B. W. (A)	685
Fluorescence of <i>Mycobacterium leprae</i> . Padilla, M. A. and Sanchez, J. L. (A)	340
Growth of <i>Mycobacterium leprae</i> in a redox system. Chatterjee, B. R. (A)	685
Host-grown <i>Mycobacterium leprae</i> . A credible microorganism. Draper, P. (A)	345
Host responses to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., et al. (A)	710
Human monoclonal antibodies against <i>Mycobacterium leprae</i> . Atlaw, T., et al. (A)	677
Hydrolytic enzymes in macrophages from leprosy patients in presence of <i>Mycobacterium leprae</i> . Marolia, J. and Mahadevan, P. R. (A)	508
Incorporation of [¹⁴ C]-acetate into the specific phenolic glycolipid of <i>M. leprae</i> maintained within cultured cells. Mukherjee, R., et al. (A)	508
Identification of cloned <i>Mycobacterium leprae</i> genes in <i>Escherichia coli</i> . Jacobs, W. R., et al. (A)	711
IgM antibodies against phenolic glycolipid I from <i>Mycobacterium leprae</i> in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., et al. (A)	341
Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to <i>Mycobacterium leprae</i> . Douglas-Jones, A. G. and Watson, J. D. (O)	412
Immunochemical characterization of a protein associated with <i>Mycobacterium leprae</i> cell wall. Gillis, T. P., et al. (A)	679
Immunofluorescence studies on <i>Mycobacterium leprae</i> in fixed tissues. Krotoski, W. A. and McCormick, G. T. (A)	177
Immunologic assessment of <i>Mycobacterium leprae</i> antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. (A)	173
<i>In vitro</i> drug screening system using membrane alteration in macrophages by <i>Mycobacterium leprae</i> . Mankar, M. V., et al. (A)	507
<i>In vitro</i> lymphocyte stimulating ability of cell components of <i>Mycobacterium leprae</i> . Khandke, L., et al. (A)	337
<i>In vivo</i> responses to <i>Mycobacterium leprae</i> : antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., et al. (O)	385
Influence of levamisole on lymphocytes and <i>M. leprae</i> in mice. Ganguly, N. K., et al. (A)	689
Interleukin-2-induced T-cell response to <i>M. leprae</i> in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small <i>M. leprae</i> -reactive T-cell pool? Shankar, P., et al. (C)	649
Isolation and preliminary characterization of the major intracellular carbohydrate-containing antigens of <i>Mycobacterium leprae</i> . Hunter, S. W., et al. (A)	712
Isolation of characteristic glycolipids possibly included in spherical droplets around <i>M. leprae</i> . Fukunishi, Y., et al. (O)	447

Leprosy in sub-human primates: potential risk for transfer of <i>M. leprae</i> to humans. Hagstad, H. V. (A)	147
Lipase and penicillinase activity in <i>Mycobacterium leprae</i> . Talati, S. and Mahadevan, P. R. (A)	509
Lymphocyte suppression in leprosy induced by unique <i>M. leprae</i> glycolipid. Mehra, V., et al. (A)	680
Macrophage activity in <i>Mycobacterium leprae</i> infection. Sharp, A. K. and Banerjee, D. K. (A)	341
Macrophage interaction with mycobacteria including <i>M. leprae</i> . Ryter, A., et al. (A)	346
Malonyl-CoA decarboxylase activity in <i>Mycobacterium leprae</i> . Harris, E. B. and Prabhakaran, K. (A)	165
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from <i>M. leprae</i> . Samuel, N. M., et al. (O)	395
Molecular analysis of DNA and construction of genomic libraries of <i>Mycobacterium leprae</i> . Clark-Curtiss, J. E., et al. (A)	344
Monoclonal antibodies to a 28,000 mol. wt protein antigen of <i>Mycobacterium leprae</i> . Young, D. B., et al. (A)	684
Morphometrical characteristics of <i>M. leprae</i> and <i>M. lepraemurium</i> intracytoplasmatic inclusions. Maslov, A. K. (A)	508
<i>Mycobacterium leprae</i> in seminal fluid: a case report. Pareek, S. S. and Al-Nozha, M. (A)	500
<i>Mycobacterium leprae</i> —the outer lipoidal surface. Brennan, P. J. (A)	685
<i>Mycobacterium leprae</i> within a squamous cell carcinoma. Laing, A. B. G., et al. (A)	333
Periodic acid-Schiff reaction stains <i>Mycobacterium tuberculosis</i> , <i>M. leprae</i> , <i>M. ulcerans</i> , <i>M. chelonae</i> (abscessus), and <i>M. kansasii</i> . Wear, D. J., et al. (A)	684
Phagocytic and bactericidal activities of macrophages from <i>Mycobacterium leprae</i> -infected normal and immunosuppressed mice. Vaishnavi, C., et al. (O)	233
Phagocytosis of <i>Mycobacterium leprae</i> and <i>M. avium</i> by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. (A)	340
Phenolic glycolipid 1 of <i>Mycobacterium leprae</i> causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., et al. (A)	139
Production of human antibodies to <i>Mycobacterium leprae</i> . Mohagheghpour, N., et al. (A)	717
Production of human monoclonal antibodies to <i>Mycobacterium leprae</i> . Mohagheghpour, N., et al. (A)	178
Quantitative comparison of the mycolic and fatty acid compositions of <i>Mycobacterium leprae</i> and <i>M. gordonae</i> . Minnikin, D. E., et al. (A)	687
Rapid detection of mycobacterial contamination in batches of whole cells of purified <i>Mycobacterium leprae</i> by pyrolysis gas chromatography. Wieten, G., et al. (A)	348
Recombinant DNA clones expressing <i>M. leprae</i> and <i>M. tuberculosis</i> antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., et al. (A)	727
Respiration in <i>Mycobacterium leprae</i> . Mori, T., et al. (O)	600
Response to Dr. Grosset, et al. (drug sensitivity testing of <i>M. leprae</i>). Almeida, J. G. and Chacko, C. J. G. (C)	120
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of <i>M. leprae</i> for drug sensitivity testing: a comparison. Seydel, U., et al. (O)	365
Results of a World Health Organization-sponsored workshop on monoclonal antibodies to <i>Mycobacterium leprae</i> (A)	682
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to <i>Mycobacterium leprae</i> . Haregewoin, A., et al. (A)	141
Reversal reactions in <i>M. leprae</i> -infected nine-banded armadillos. Juscenko, A. A. (A)	510
Salivary anti- <i>M. leprae</i> antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., et al. (A)	715
Some new data on <i>Mycobacterium leprae</i> biology. Juscenko, A. A. (A)	507
Species-specific epitopes on protein molecules of <i>Mycobacterium leprae</i> or <i>M. tuberculosis</i> : elucidation with monoclonal antibodies. Buchanan, T. M. (A)	715
Strain variation in murine immune response to the <i>M. leprae</i> glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., et al. (A)	721
Studies on antimicrobial activity against <i>M. leprae</i> infections of the mouse foot pad. Gelber, R. H. (A)	171

- Study on the micromorphology of *Mycobacterium leprae*. Burchard, G.-D. and Bierther, M. (A) 685
- Susceptibility of *Mycobacterium leprae* to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., *et al.* (A) 342
- Synergistic activity of dapsone and brodimoprim (a dihydrofolate inhibitor) against *Mycobacterium leprae*. Jagannathan, R. and Mahadevan, P. R. (A) 495
- Temperature effects on viability, diphenoloxidase, and permeability of *Mycobacterium leprae*. Prabhakaran, K. and Harris, E. B. (A) 168
- Temperature-induced changes in viability, diphenoloxidase and permeability of *Mycobacterium leprae*. Prabhakaran, K. and Harris, E. B. (A) 688
- The adenosine triphosphate content and death rate of *Mycobacterium leprae* isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., *et al.* (A) 169
- The bactericidal activity of various aminoglycoside antibiotics against *Mycobacterium leprae* in mice. Gelber, R. H., *et al.* (A) 328
- The discovery of *Mycobacterium leprae*. A medical achievement in the light of evolving scientific methods. Irgens, L. M. (A) 326
- The effect of *Mycobacterium leprae* on PHA- and PPD-induced inhibition of leucocyte migration in leprosy patients. Dharma Rao, T., *et al.* (A) 679
- The free lipids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., *et al.* (A) 686
- The influence of ultrasonication of *M. leprae* growth. Badovskaya, Z. V. (A) 507
- The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae*. Ji, B., *et al.* (A) 357
- The synthesis and activity of the sugar derivatives to phenolic glycolipids of *Mycobacterium leprae* and preparation of sugar-protein conjugates. Fujiwara, T., *et al.* (A) 727
- Three histologic fixatives for the demonstration of *Mycobacterium leprae*. Jones, R. L. and McDougall, A. C. (A) 337
- Trials of culturing of *Mycobacterium leprae* using media enriched with thyroid hormones. Massalski, W., *et al.* (A) 145
- Trophic changes and extensive dissemination in normal mice with human *Mycobacterium leprae*. Vaishnavi, C., *et al.* (A) 510
- Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. (A) 338
- Use of a polysulfone membrane support for immunochemical analysis of a glycolipid from *Mycobacterium leprae*. Young, D. B., *et al.* (A) 684
- Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare*, and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* (O) 441
- Mycobacterium lepraemurium*,**
- A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. (A) 138
- An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* (A) 691
- Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. (A) 348
- Delayed-type hypersensitivity after immunization with ultrasonicated *Mycobacterium lepraemurium* in C3H and C57BL mice. Lovik, M., *et al.* (A) 351
- Deoxyribonucleic acid relatedness among *Mycobacterium leprae*, *Mycobacterium lepraemurium*, and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., *et al.* (A) 342
- Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. (A) 345
- Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium* *in vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* (A) 353
- H-2-linked genes which modify resistance of C57BL/10 mice to subcutaneous infection with *Mycobacterium lepraemurium*. Curtis, J., *et al.* (A) 146

Immune response in BALB/c mice following immunization with heat-killed <i>Mycobacterium lepraemurium</i> . Graham, L. and Navalkar, R. G. (A)	146
Induction of gamma interferon with various mitogens in mice pretreated with <i>M. lepraemurium</i> and the effect of <i>in vivo</i> interferon production on the growth of <i>M. lepraemurium</i> in mice. Nomaguchi, H., <i>et al.</i> (A)	706
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with <i>Mycobacterium lepraemurium</i> . Hoffenbach, A., <i>et al.</i> (A)	349
Influence of dose and route of <i>Mycobacterium lepraemurium</i> inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., <i>et al.</i> (A)	679
Intrinsic energy potential of <i>Mycobacterium lepraemurium</i> essential for growth in MC-5 medium. Nakamura, M. and Dhople, A. M. (A)	687
Isolation of mycobacterial phage from the laboratory strain <i>Mycobacterium lepraemurium</i> "Douglas." Sula, L., <i>et al.</i> (A)	509
Lytic potency against various mycobacterial strains of the phage isolated from <i>Mycobacterium lepraemurium</i> "Douglas." Sula, L. and Sulova, J. (A)	509
Macrophage activation in mice infected with <i>Mycobacterium lepraemurium</i> . Brett, S. J. (A)	349
Morphometrical characteristics of <i>M. leprae</i> and <i>M. lepraemurium</i> intracytoplasmatic inclusions. Maslov, A. K. (A)	508
<i>Mycobacterium lepraemurium</i> infection of nude athymic (nu/nu) mice. Lefford, M. J. (A)	690
Serum enzymatic changes following infection of mice with <i>Mycobacterium lepraemurium</i> . Rojas-Espinosa, O., <i>et al.</i> (O)	258
Strain variation of lymphokine production and specific antibody secretion in mice infected with <i>Mycobacterium lepraemurium</i> . Hoffenbach, A., <i>et al.</i> (A)	510
Survival of <i>Mycobacterium lepraemurium in vitro</i> for thirty years by lyophilization. Nakamura, M. (O)	52
T-cell responsiveness in <i>Mycobacterium lepraemurium</i> infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J. (A)	349
Use of fluorescent staining method for determining the viability of <i>Mycobacterium lepraemurium</i> . Tsukiyama, F., <i>et al.</i> (A)	347
Use of gas chromatography to differentiate <i>Mycobacterium leprae</i> from cultivable armadillo-derived mycobacteria, <i>M. avium/intracellulare</i> , and <i>M. lepraemurium</i> by analysis of secondary alcohols. Larsson, L., <i>et al.</i> (O)	441
"<i>Mycobacterium lufu</i>,"	
The use of " <i>M. lufu</i> " for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. (A)	494
<i>Mycobacterium szulgai</i>,	
Cutaneous <i>Mycobacterium szulgai</i> infection. Cross, G. M., <i>et al.</i> (A)	361
<i>Mycobacterium tuberculosis</i>,	
Detection of an antigen (MY4) common to <i>M. tuberculosis</i> and <i>M. leprae</i> by "tandem" immunoassay. Praputpittaya, L. and Ivanyi, J. (A)	681
Determination of <i>in vitro</i> susceptibility of <i>Mycobacterium tuberculosis</i> to cephalosporins by radiometric and conventional methods. Heifets, L. B., <i>et al.</i> (A)	361
Dissection of <i>Mycobacterium tuberculosis</i> antigens using recombinant DNA. Young, R. A., <i>et al.</i> (A)	699
Fixation of <i>Mycobacterium leprae</i> in unstained smears prior to shipment or storage: evaluation of formaldehyde using <i>Mycobacterium tuberculosis</i> as indicator of efficacy. Allen, B. W. (A)	685
<i>In vitro</i> activity of ampicillin compared to ampicillin and sulbactam against <i>Mycobacterium tuberculosis</i> . Cynamon, M. H., <i>et al.</i> (A)	165
Periodic acid-Schiff reaction stains <i>Mycobacterium tuberculosis</i> , <i>M. leprae</i> , <i>M. ulcerans</i> , <i>M. chelonae (abscessus)</i> , and <i>M. kansasii</i> . Wear, D. J., <i>et al.</i> (A)	684
Recombinant DNA clones expressing <i>M. leprae</i> and <i>M. tuberculosis</i> antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., <i>et al.</i> (A)	727

- Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of *Mycobacterium tuberculosis*. Goren, M. B., *et al.* (A) 150
- Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* (A) 360
- Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. (A) 715
- Mycobacterium ulcerans*,**
- Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis*, *M. leprae*, *M. ulcerans*, *M. chelonae* (abscessus), and *M. kansasii*. Wear, D. J., *et al.* (A) 684
- Mycobactin,**
- Absence of mycobactin in *Mycobacterium leprae*; probably a microbe dependent microorganism. Implications. Kato, L. (A) 686
- Nepal,**
- A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., *et al.* (A) 143
- Leprosy treatment in Nepal with multidrug regimens. Birch, M. C. (A) 133
- Multidrug treatment of leprosy—practical application in Nepal. Samuel, N. M., *et al.* (A) 136
- Prevalence of secondary dapsone resistance in Nepal. Samuel, N. M., *et al.* (A) 497
- Primary dapsone resistant leprosy in Nepal. Samuel, N. M., *et al.* (A) 497
- Social factors and leprosy in Lamjung, west central Nepal: implication for disease control. Pearson, M. (A) 358
- Nerve(s),**
- A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. (A) 506
- Digital dermatoglyphics in leprosy patients with severe nerve damage. Baranov, Y. N., *et al.* (A) 498
- Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. (O) 75
- Median nerve function after tendon transfer for ulnar paralysis. Brandsma, J. W. and Brand, P. W. (A) 513
- Muramidase (lysozyme) findings in sural and radial nerve biopsies in leprosy patients after varying periods of treatment. Haimanot, R. T., *et al.* (O) 238
- Neural auto-antibodies in leprosy. Eustis-Turf, E. P., *et al.* (A) 722
- Neurolysis of the common peroneal nerve in leprosy. A report on 22 patients. Chaise, F. and Roger, B. (A) 694
- Rabbit sural nerve responses to chronic treatment with thalidomide and suplidimide. Schwab, B. W., *et al.* (A) 330
- Surgical decompression of the ulnar nerve. Srinivasan, H. (A) 359
- Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. (A) 513
- The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., *et al.* (A) 674
- The treatment of early nerve damages due to leprosy. Alamdarov, I. N., *et al.* (A) 512
- Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddington, J. (A) 138
- Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. (A) 338
- Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., *et al.* (A) 506
- Neuropathy,**
- Acute severe peripheral neuropathy due to thiacetazone. Gupta, P. K., *et al.* (A) 328
- Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* (C) 481

Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. (A)	672
Neuropathic plantar ulceration. Kumar, K., <i>et al.</i> (A)	694
Nueropathic ulcers of the foot. Lang-Stevenson, A. I., <i>et al.</i> (A)	694
Thalidomide-induced peripheral neuropathy. Aronson, I. K., <i>et al.</i> (A)	148
Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddington, J. (A)	138
Weight appreciation in the hand in normal subjects and in patients with leprosy neuropathy. Raj, D. V., <i>et al.</i> (A)	675
New Zealand,	
Leprosy in New Zealand. Woodward, W. (A)	667
Nigeria,	
Social aspects of leprosy: a case study in Zaria, northern Nigeria. Reddy, N. B. B., <i>et al.</i> (A)	513
Nose,	
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. (O)	577
Nutrition,	
Geographical variations in the occurrence of leprosy: possible roles played by nutrition and some other environmental factors. Sommerfelt, H., <i>et al.</i> (O)	524
Nutritional aspects of leprosy. Mester de Parajd, L. and Garnier, J.-P. (A)	329
Obituaries,	
Nishiura, Mitsugu. (Ob)	308
Pedley, James Cecil. (Ob)	641
Shepard, Charles C. (Ob)	309
Pakistan,	
Analysis of leprosy control program. Pfau, R. (A)	512
Pathology,	
Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., <i>et al.</i> (A)	499
Peroxidase,	
Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., <i>et al.</i> (A)	699
Peru,	
Operational evaluation of treatment for tuberculosis: results of a "standard" 12-month regimen in Peru. Hopewell, P. C., <i>et al.</i> (A)	696
Phagocytes,	
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., <i>et al.</i> (A)	503
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., <i>et al.</i> ... (A)	330
Phagocytic and bactericidal activities of macrophages from <i>Mycobacterium leprae</i> -infected normal and immunosuppressed mice. Vaishnavi, C., <i>et al.</i> (O)	233
Phagocytosis of <i>Mycobacterium leprae</i> and <i>M. avium</i> by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. (A)	340
Phenolic glycolipid(s),	
A diverse approach to the serodiagnosis of leprosy based on the phenolic glycolipid-I. Cho, S.-N., <i>et al.</i> (A)	715
Antibody response to phenolic glycolipid I in inbred mice immunized with <i>Mycobacterium leprae</i> . Teuscher, C., <i>et al.</i> (A)	683
Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., <i>et al.</i> (O)	211
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	175

ELISA evaluation of phenolic glycolipid-I (PGI) and whole <i>M. leprae</i> with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., <i>et al.</i> (A)	180
Host responses to the phenolic glycolipid-I antigen of <i>M. leprae</i> . Truman, R. W., <i>et al.</i> (A)	710
IgM antibodies against phenolic glycolipid I from <i>Mycobacterium leprae</i> in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., <i>et al.</i> (A)	341
Incorporation of [¹⁴ C]-acetate into the specific phenolic glycolipid of <i>M. leprae</i> maintained within cultured cells. Mukherjee, R., <i>et al.</i> (A)	508
Isolation of phenolic glycolipid-I from human lepromatous nodules. Vemuri, N., <i>et al.</i> (C)	487
Phenolic glycolipid-I: an immunogen for a Mitsuda response. Job, C. K., <i>et al.</i> (A)	179
Phenolic glycolipid I now available in limited quantities (from IMMLEP Bank, London). (N)	319
Phenolic glycolipid I of <i>Mycobacterium leprae</i> causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., <i>et al.</i> (A)	139
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., <i>et al.</i> (C)	484
Strain variation in murine immune response to the <i>M. leprae</i> glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., <i>et al.</i> (A)	721
The synthesis and activity of the sugar derivatives to phenolic glycolipids of <i>Mycobacterium leprae</i> and preparation of sugar-protein conjugates. Fujiwara, T., <i>et al.</i> (A)	727
Phenotypes,	
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., <i>et al.</i> (A)	504
<i>In vivo</i> responses to <i>Mycobacterium leprae</i> : antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., <i>et al.</i> (O)	385
Phospholipids,	
Essential fatty acids in the plasma phospholipids of patients with leprosy. Wright, S. (A)	677
Prostaglandin,	
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E ₂ by human polymorphonuclear leukocytes <i>in vitro</i> . Anderson, R. (A)	327
Protein(s),	
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O)	22
Affinity purification of a 65,000 dalton protein of <i>Mycobacterium gordonae</i> using a monoclonal antibody which recognizes a shared epitope on the homologous protein of <i>Mycobacterium leprae</i> . Gillis, T. P. (A)	718
Immunochemical characterization of a protein associated with <i>Mycobacterium leprae</i> cell wall. Gillis, T. P., <i>et al.</i> (A)	679
Monoclonal antibodies to a 28,000 mol. wt protein antigen of <i>Mycobacterium leprae</i> . Young, D. B., <i>et al.</i> (A)	684
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
Species-specific epitopes on protein molecules of <i>Mycobacterium leprae</i> or <i>M. tuberculosis</i> : elucidation with monoclonal antibodies. Buchanan, T. M. (A)	715
The synthesis and activity of the sugar derivatives to phenolic glycolipids of <i>Mycobacterium leprae</i> and preparation of sugar-protein conjugates. Fujiwara, T., <i>et al.</i> (A)	727
Prothionamide,	
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., <i>et al.</i> (A)	494
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., <i>et al.</i> (A)	669
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., <i>et al.</i> (A)	134

Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., <i>et al.</i> (O)	15
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., <i>et al.</i> (A)	669
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A)	134
Prurigo nodularis,	
Thalidomide treatment of prurigo nodularis. Winkelmann, R. K., <i>et al.</i> (A)	153
Psychosocial,	
Psychosocial stress in Hansen's disease: a comparison with other chronic illness patients. Bahlinger, V. M., <i>et al.</i> (O)	251
Purification,	
Affinity purification of a 65,000 dalton protein of <i>Mycobacterium gordonae</i> using a monoclonal antibody which recognizes a shared epitope on the homologous protein of <i>Mycobacterium leprae</i> . Gillis, T. P. (A)	718
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., <i>et al.</i> (C)	484
Purified protein derivative (PPD),	
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
The effect of <i>Mycobacterium leprae</i> on PHA- and PPD-induced inhibition of leucocyte migration in leprosy patients. Dharma Rao, T., <i>et al.</i> (A)	679
Radioimmunoassay,	
Anti- <i>Mycobacterium leprae</i> antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., <i>et al.</i> (A)	144
Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., <i>et al.</i> (A)	676
Radiolabel,	
Alternate radiolabeled markers for detecting metabolic activity of <i>Mycobacterium leprae</i> residing in murine macrophages. Prasad, H. K. and Hastings, R. C. (A)	688
Characterization of a competitive-antibody-binding assay with a radiolabeled mono- clonal antibody specific for <i>Mycobacterium leprae</i> . Gillis, T. P., <i>et al.</i> (A)	178
Rat(s),	
Effects of <i>Mycobacterium leprae</i> vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. (A)	174
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. (A)	719
Reaction(s),	
A new method for testing tuberculin skin reactivity—chamber test. Backman, A., <i>et al.</i> (A)	360
A sequential histopathological study of the lepromin reaction in leprosy patients. Mistry, N. F., <i>et al.</i> (A)	680
An <i>in situ</i> immunohistological study of Mitsuda reactions. Dugan, E., <i>et al.</i> (O)	404
Assessment of sensitin from <i>M. leprae</i> by cell-mediated and humoral immune reactions. Dyachina, M. N., <i>et al.</i> (A)	502
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., <i>et al.</i> (C)	113
Evidence for the presence of <i>M. leprae</i> reactive T lymphocytes in patients with lep- romatous leprosy. Nath, I., <i>et al.</i> (A)	340
Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. (O)	546

Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., <i>et al.</i> (O)	540
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. (A)	329
Interleukin-2-induced T-cell response to <i>M. leprae</i> in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small <i>M. leprae</i> -reactive T-cell pool? Shankar, P., <i>et al.</i> (C)	649
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from <i>M. leprae</i> . Samuel, N. M., <i>et al.</i> (O)	395
Periodic acid-Schiff reaction stains <i>Mycobacterium tuberculosis</i> , <i>M. leprae</i> , <i>M. ulcerans</i> , <i>M. chelonae</i> (abscessus), and <i>M. kansasii</i> . Wear, D. J., <i>et al.</i> (A)	684
Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. (A)	149
Reaction, leprosy,	
A case of type 2 leprosy reactions accompanied by purpura. Chen, J., <i>et al.</i> (A)	136
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanan, T. and Rajan, M. A. (A)	677
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., <i>et al.</i> (A)	504
Enzyme immunoassay of serum β -2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., <i>et al.</i> (A)	505
Late reversal reaction after combined treatment of a patient with multibacillary leprosy. Pattyn, S. R., <i>et al.</i> (A)	334
Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., <i>et al.</i> (A)	676
Reversal reactions in <i>M. leprae</i> -infected nine-banded armadillos. Juscenko, A. A. (A)	510
Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. (C)	313
Successful plasma exchange in type 1 leprosy reversal reaction. Lucht, F., <i>et al.</i> (A)	500
The use of colchicine in the management of type 2 lepra reaction (erythema nodosum leprosum). Stanley, J. N. A., <i>et al.</i> (A)	136
Refugees,	
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Specific health problems of Southeast Asian refugees in middle Tennessee (U.S.A.). Dao, A. H., <i>et al.</i> (A)	132
Rehabilitation,	
<i>Surgical Reconstruction and Rehabilitation in Leprosy.</i> Fritschi, E. P. (B)	129
Relapse(s),	
A study of relapse in nonlepromatous and intermediate groups of leprosy. Pandian, T. D., <i>et al.</i> (A)	671
Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnenjuk, T. S. (A)	494
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. (O)	189
Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy. Jesudasan, J. and Christian, M. (O)	19
The analysis of causes of relapses in leprosy. Kadantsev, N. D. and Kogan, V. R. (A)	495
Respiration,	
Respiratory dysautonomia in leprosy. Gupta, O. P., <i>et al.</i> (A)	499
The changes in upper respiratory organs in the discharged patients with "burnt out" lepromatous leprosy. Kaipbergenov, U. K. (A)	499
Rifampin,	
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O)	22

Acute rifampin overdose: a pharmacokinetic study and review of the literature. Wong, P., <i>et al.</i> (A)	497
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., <i>et al.</i> (A)	494
Effect of antacids on oral absorption of rifampicin. Khalil, S. A. H., <i>et al.</i> (A)	669
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with <i>Mycobacterium leprae</i> . Sebille, A., <i>et al.</i> (C)	481
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., <i>et al.</i> (A)	134
Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., <i>et al.</i> (O)	15
<i>In vitro</i> cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. (A)	493
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., <i>et al.</i> (O)	421
Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Kar, H. K. and Roy, R. G. (A)	495
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A)	134
Rifamycin,	
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O)	22
Novel rifamycins. IV. 3-Aminomethylazino-methylrifamycins, a new class of rifamycins, endowed with remarkable antibacterial activity. Marsili, I., <i>et al.</i> (A)	135
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A)	134
Saliva,	
Salivary anti- <i>M. leprae</i> antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., <i>et al.</i> (A)	715
Screening: for leprosy,	
<i>In vitro</i> drug screening system using membrane alteration in macrophages by <i>Mycobacterium leprae</i> . Mankar, M. V., <i>et al.</i> (A)	507
The use of " <i>M. lufu</i> " for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. (A)	494
Sensation(s),	
Minimum temperature felt as hot (MTH)—a new concept for grading the loss of temperature sensation in leprosy patients. Jain, G. L., <i>et al.</i> (O)	206
Sensitivity, drug,	
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., <i>et al.</i> (A)	349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., <i>et al.</i> (A)	172
An <i>in vitro</i> test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of <i>Mycobacterium leprae</i> . Nair, I. and Mahadevan, P. R. (A)	671
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of <i>Mycobacterium leprae</i> sensitivity/resistance to dapsone. Sathish, M., <i>et al.</i> (O)	378
Drug sensitivity testing of <i>M. leprae</i> . Grosset, J., <i>et al.</i> (C)	118
Response to Dr. Grosset, <i>et al.</i> (drug sensitivity testing of <i>M. leprae</i>). Almeida, J. G. and Chacko, C. J. G. (C)	120

Results from cation and mass fingerprint analysis of single cells and from ATP measurements of <i>M. leprae</i> for drug sensitivity testing: a comparison. Seydel, U., <i>et al.</i> (O)	365
Serodiagnosis,	
A diverse approach to the serodiagnosis of leprosy based on the phenolic glycolipid-I. Cho, S.-N., <i>et al.</i> (A)	715
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
Use of an artificial antigen containing the 3,6-di- <i>O</i> -methyl- β -D-glucopyranosyl epitope for the serodiagnosis of leprosy. Cho, S.-N., <i>et al.</i> (A)	139
Serum,	
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O)	22
Biochemical alterations in the serum of armadillos (<i>Dasypus novemcinctus</i>) infected with <i>Mycobacterium leprae</i> . A preliminary report. Rojas-Espinosa, O., <i>et al.</i> (O)	262
Conversion of the C3 component of complement in sera of hanseniasis patients. Kliemann, T. A. E., <i>et al.</i> (A)	142
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., <i>et al.</i> (A)	137
Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy patients' sera. Furukawa, F., <i>et al.</i> (C)	647
Effect of leprosy sera and foetal calf serum (FCS) on the T cell number of peripheral blood of leprosy patients. Patil, S. A., <i>et al.</i> (A)	504
ELISA evaluation of phenolic glycolipid-I (PGI) and whole <i>M. leprae</i> with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., <i>et al.</i> (A)	180
Enzyme immunoassay of serum β -2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., <i>et al.</i> (A)	505
IgM antibodies against phenolic glycolipid I from <i>Mycobacterium leprae</i> in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., <i>et al.</i> (A)	341
Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., <i>et al.</i> (O)	218
Myelinotoxic effect of serum antibodies from leprosy patients. Umerov, G. G., <i>et al.</i> (A)	506
Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., <i>et al.</i> (A)	676
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., <i>et al.</i> (A)	151
Serum enzymatic changes following infection of mice with <i>Mycobacterium lepraemurium</i> . Rojas-Espinosa, O., <i>et al.</i> (O)	258
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., <i>et al.</i> (O)	225
Serum soluble interleukin-2 receptors in leprosy patients. Tung, K. S. K., <i>et al.</i> (A)	719
Sexual dysfunction,	
Behavioral analysis of sexual dysfunction in Hansen's disease. Faulstich, M. E. (A)	674
Skin,	
A new method for testing tuberculin skin reactivity—chamber test. Backman, A., <i>et al.</i> (A)	360
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., <i>et al.</i> (O)	554
Chromosomal aberrations in cultures of skin fibroblasts of leprosy patients. Hackel, C. and Beiguelman, B. (O)	533
Comparison of S-100 and OKT6 antisera in human skin. Modlin, R. L., <i>et al.</i> (A)	389
Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., <i>et al.</i> (A)	683
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	707

Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., <i>et al.</i> (A)	678
Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Cree, I. A., <i>et al.</i> (O)	582
Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., <i>et al.</i> (O)	373
Skin tests,	
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., <i>et al.</i> (A)	143
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from <i>M. leprae</i> . Samuel, N. M., <i>et al.</i> (O)	395
Skin-test sensitisation by tubercle bacilli and by other mycobacteria in Ethiopian school-children. Eshetu Lema and Stanford, J. (A)	362
Social,	
The relationship between perceived social support and illness reports in Hansen's disease patients. Williams, K., <i>et al.</i> (A)	162
Southeast Asia,	
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Specific health problems of Southeast Asian refugees in middle Tennessee (U.S.A.). Dao, A. H., <i>et al.</i> (A)	132
Spain,	
El Doctor Jose Terencio de las Aguas, experto en lepra de la Organizacion Mundial de la Salud. (N)	125
Fontilles celebrates 75th anniversary. (N)	125
Spleen,	
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., <i>et al.</i> (A)	146
Stain(s),	
A specific glucose oxidase immunoenzyme stain for <i>Mycobacterium leprae</i> . Long, E. G., <i>et al.</i> (A)	176
Periodic acid-Schiff reaction stains <i>Mycobacterium tuberculosis</i> , <i>M. leprae</i> , <i>M. ulcerans</i> , <i>M. chelonae</i> (abscessus), and <i>M. kansasii</i> . Wear, D. J., <i>et al.</i> (A)	684
Use of fluorescent staining method for determining the viability of <i>Mycobacterium lepraemurium</i> . Tsukiyama, F., <i>et al.</i> (A)	347
Steroid(s),	
Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. (C)	313
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., <i>et al.</i> (A)	674
Subclinical,	
Extended studies on subclinical infection in leprosy. Bharadwaj, V. P., <i>et al.</i> (A)	510
The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with <i>Mycobacterium leprae</i> . Ji, B., <i>et al.</i> (A)	357
Superoxide dismutase,	
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., <i>et al.</i> (A)	330
Supidimide,	
Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., <i>et al.</i> (A)	330
Suppression,	
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., <i>et al.</i> (A)	143
Hypothesis: possible idiopathic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., <i>et al.</i> (A)	140

- In vitro* cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., *et al.* (A) 709
- Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* (C) 649
- Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* (A) 707
- Lymphocyte suppression in leprosy induced by unique *M. leprae* glycolipid. Mehra, V., *et al.* (A) 680
- Specific suppression of responses to *Leishmania tropica* by a cloned T-cell line. Liew, F. Y. (A) 362
- Surgery,**
- Reconstruction of the heel with chronic ulceration with flexor digitorum brevis myocutaneous flap. Shuh, A. and Pandit, S. (A) 513
- Silastic imprint of the first dorsal interosseous space. Zacharia, A. G. and Gelber, R. H. (C) 643
- Surgical decompression of the ulnar nerve. Srinivasan, H. (A) 359
- Surgical Reconstruction and Rehabilitation in Leprosy.* Fritschi, E. P. (B) 129
- Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. (A) 513
- Switzerland,**
- Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy meeting, 10–11 October 1983. (N) 125
- Tropical Disease Research Program seventh report published. (N) 660
- WHO meeting on multidrug therapy. (N) 126
- Systemic lupus erythematosus (SLE),**
- Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* (A) 137
- Lepromatous leprosy complicated with systemic lupus erythematosus. Ohkawa, S., *et al.* (A) 675
- Temperature,**
- Minimum temperature felt as hot (MTH)—a new concept for grading the loss of temperature sensation in leprosy patients. Jain, G. L., *et al.* (O) 206
- Temperature effects on viability, diphenoxidase, and permeability of *Mycobacterium leprae*. Prabhakaran, L. and Harris, E. B. (A) 168
- Temperature-induced changes in viability, diphenoxidase and permeability of *Mycobacterium leprae*. Prabhakaran, K. and Harris, E. B. (A) 688
- Thailand,**
- Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schaaf, V., *et al.* (A) 163
- Thalidomide,**
- Development of polyneuropathy during thalidomide therapy. Wulff, C. H., *et al.* (A) 514
- Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* (A) 165
- Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. (A) 672
- Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., *et al.* (A) 330
- Thalidomide. A promising new treatment for rheumatoid arthritis. Gutierrez-Rodriguez, O. (A) 151
- Thalidomide enhances defective monocyte function in lepromatous leprosy. Nielsen, H. and Bennike, T. (A) 135
- Thalidomide in severe orogenital ulceration. Jenkins, J. S., *et al.* (A) 362
- Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae. Kurkcuoglu, N., *et al.* (A) 696
- Thalidomide induces imbalances in T lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* (A) 502
- Thalidomide treatment of prurigo nodularis. Winkelmann, R. K., *et al.* (A) 153

Thalidomide—effect on T cell subsets as a possible mechanism of action. Moncada, B., <i>et al.</i> (O)	201
Thalidomide-induced peripheral neuropathy. Aronson, I. K., <i>et al.</i> (A)	148
The Leprosy Mission (TLM),	
The Leprosy Mission International's Teaching and Learning Materials in Leprosy. Neville, J. (N)	321
THELEP,	
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O)	22
Therapy, see also Chemotherapy,	
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., <i>et al.</i> (A)	349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., <i>et al.</i> (A)	172
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., <i>et al.</i> (A)	494
Development of polyneuropathy during thalidomide therapy. Wulff, C. H., <i>et al.</i> (A)	514
Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnenjuk, T. S. (A)	494
Drug interactions in combined antileprosy therapy. Loginov, V. K., <i>et al.</i> (A)	496
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., <i>et al.</i> (C)	113
Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. (A)	608
Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Mathur, A., <i>et al.</i> (A)	670
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., <i>et al.</i> (A)	669
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., <i>et al.</i> (A)	134
Managerial implications of multidrug therapy. Askew, A. D. (A)	668
Monitoring compliance with anti-tuberculosis therapy. Pitchenik, A. E. (A)	135
Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. (A)	329
Multidrug therapy for multibacillary cases in Wardha District, Maharashtra, India. Nilakanta Rao, M. S. and Yellapurkar, M. V. (A)	671
Norethisterone and ethinyl estradiol kinetics during dapsone therapy. Joshi, J. V., <i>et al.</i> (A)	328
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., <i>et al.</i> . . (A)	669
The assessment of activity of leprosy process and effectiveness of antileprosy therapy by excess lactate in blood. Ryzhova, N. Y. (A)	501
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A. (A)	503
The pharmacology of intermittent clofazimine therapy in Hansen's disease. Morales, M. J., <i>et al.</i> (A)	166
WHO meeting on multidrug therapy. (N)	126
Thiacetazone,	
Acute severe peripheral neuropathy due to thiacetazone. Gupta, P. K., <i>et al.</i> (A)	328
Thioamide,	
An experimental study of the antileprosy activity of a series of thioamides in the mouse. Shepard, C. C., <i>et al.</i> (O)	587
Tilorone,	
A dual effect of tilorone on multiplication of <i>Mycobacterium leprae</i> in mice. Levy, L. and Aizer, F. (A)	350

Tissue(s),

- Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* (A) 508
- Immunofluorescence studies on *Mycobacterium leprae* in fixed tissues. Krotoski, W. A. and McCormick, G. T. (A) 177
- In vitro* cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. (A) 493
- The adenosine triphosphate content and death rate of *Mycobacterium leprae* isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., *et al.* (A) 169
- Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* (A) 338

Tobago,

- Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. (A) 329

Toxicity,

- Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A) 134

Training,

- Hansenologia* (textbook on leprosy). Talhari, S. and Neves, R. G. (B) 131
- IILEP Catalogue on Training, 1985. (N) 490
- Schieffelin Leprosy Research and Training Centre, Karigiri, 1985–1986 Course Schedule (India). (N) 320
- Teaching and Learning in Leprosy. O'Connor, R. J. (N) 664
- Training workshop held (India). Christian, M. (N) 660

Transfer,

- Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* (A) 720
- Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A) 502
- Median nerve function after tendon transfer for ulnar paralysis. Brandsma, J. W. and Brand, P. W. (A) 513
- Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., *et al.* (A) 514

Trial(s),

- Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. (O) 22
- Antileprosy vaccines—field trials and future prospects. Deo, M. G. (A) 502
- New leprosy vaccine trial. (N) 661
- Ten year evaluation of a trial of chemoprophylaxis against tuberculosis in Frobisher Bay, Canada. Dorken, E., *et al.* (A) 149

Trinidad,

- Multidrug therapy for leprosy in Trinidad Tobago: a preliminary report. Keeler, R. F. (A) 329

Tuberculin,

- A new method for testing tuberculin skin reactivity—chamber test. Backman, A., *et al.* (A) 360
- Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. (O) 546
- Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. (A) 149
- Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* (A) 360

Tuberculoid leprosy,

Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., <i>et al.</i> (A)	504
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., <i>et al.</i> (A)	678
Short course treatment of tuberculoid cases—a feasibility study. Girdhar, B. K., <i>et al.</i> (A)	668
Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schaaf, V., <i>et al.</i> (A)	163
Vitiligo on tuberculoid patches—a case report. Misra, R. S., <i>et al.</i> (A)	333

Tuberculosis,

An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., <i>et al.</i> (A)	149
Cell-mediated immune response in intestinal tuberculosis. Bhargava, D. K., <i>et al.</i> (A)	360
Cutaneous inoculation tuberculosis secondary to "jailhouse tattooing." Horney, D. A., <i>et al.</i> (A)	514
Detection of an antigen (MY4) common to <i>M. tuberculosis</i> and <i>M. leprae</i> by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. (A)	681
Determination of <i>in vitro</i> susceptibility of <i>Mycobacterium tuberculosis</i> to cephalosporins by radiometric and conventional methods. Heifets, L. B., <i>et al.</i> (A)	361
Dissection of <i>Mycobacterium tuberculosis</i> antigens using recombinant DNA. Young, R. A., <i>et al.</i> (A)	699
Fixation of <i>Mycobacterium leprae</i> in unstained smears prior to shipment or storage: evaluation of formaldehyde using <i>Mycobacterium tuberculosis</i> as indicator of efficacy. Allen, B. W. (A)	685
Haptoglobin: an immunoregulatory role in tuberculosis? Grange, J. M., <i>et al.</i> (A)	361
<i>In vitro</i> activity of ampicillin compared to ampicillin and sulbactam against <i>Mycobacterium tuberculosis</i> . Cynamon, M. H., <i>et al.</i> (A)	165
Intra-ocular tuberculosis associated with a penetrating injury. A case report. Murray, R. I. and Daya, H. (A)	697
Molecular biology of host-parasite relationship in infectious diseases, especially in salmonellosis, tuberculosis, and leprosy. Akiyama, T. (A)	334
Monitoring compliance with anti-tuberculosis therapy. Pitchenik, A. E. (A)	135
Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. (E)	618
Operational evaluation of treatment for tuberculosis; results of a "standard" 12-month regimen in Peru. Hopewell, P. C., <i>et al.</i> (A)	696
Pattern of drug resistance in tuberculosis. Hardas, U. D. and Jayaraman, V. S. (A)	695
Periodic acid-Schiff reaction stains <i>Mycobacterium tuberculosis</i> , <i>M. leprae</i> , <i>M. ulcerans</i> , <i>M. chelonae</i> (abscessus), and <i>M. kansasii</i> . Wear, D. J., <i>et al.</i> (A)	684
Production and characterization of monoclonal antibodies to <i>Mycobacterium tuberculosis</i> . Kolk, A. H. J., <i>et al.</i> (A)	338
Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. (A)	149
Recombinant DNA clones expressing <i>M. leprae</i> and <i>M. tuberculosis</i> antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., <i>et al.</i> (A)	727
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of <i>Mycobacterium tuberculosis</i> . Goren, M. B., <i>et al.</i> (A)	150
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. (A)	697
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to <i>Mycobacterium tuberculosis</i> antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., <i>et al.</i> (A)	360
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., <i>et al.</i> (A)	151
Species-specific epitopes on protein molecules of <i>Mycobacterium leprae</i> or <i>M. tuberculosis</i> : elucidation with monoclonal antibodies. Buchanan, T. M. (A)	715
Ten year evaluation of a trial of chemoprophylaxis against tuberculosis in Frobisher Bay, Canada. Dorken, E., <i>et al.</i> (A)	149
The influence of immunosuppression and immunodeficiency on infections with leprosy and tuberculosis. Strickland, N. H. (E)	86
Tuberculosis and leprosy in antiquity: an interpretation. Manchester, K. (N)	326

Tumor(s),

- Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* (A) 146

Tunisia,

- Tendances nouvelles en leprologie, 4–6 Novembre 1985, Sousse. (N) 122

Turtle(s),

- An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* (A) 691

U.K.

- 1984 Sixth Clayton Memorial Lecture: Leprosy and the Eye. (N) 127
 Chemotherapy of Leprosy for Control Programs videotape available. (N) 126
 ILEP Catalogue on Training, 1985. (N) 490
 "Learn About Leprosy," new Leprosy Mission International booklet. (N) 127
 New edition of Dr. Browne's "Leprosy." (N) 127
 OXFAM Mini Pack available. (N) 661
 Robert Cochrane Fund for Leprosy. (N) 128
 The Leprosy Mission International's Teaching and Learning Materials in Leprosy. Neville, J. (N) 321

Ulcer(s),

- A case of squamous cell carcinoma in plantar ulcer in leprosy. Bobhate, S. K., *et al.* . . (A) 331
 Carcinoma in plantar ulcers in leprosy. Fleury, R. N. and Opromolla, D. V. A. (A) 331
 Neuropathic plantar ulceration. Kumar, K., *et al.* (A) 694
 Neuropathic ulcers of the foot. Lang-Stevenson, A. I., *et al.* (A) 694
 Reconstruction of the heel with chronic ulceration with flexor digitorum brevis myocutaneous flap. Shuh, A. and Pandit, S. (A) 513
 Squamous cell carcinoma developing trophic ulcers in leprosy—a case report. Kumar, K. and Kant, M. (A) 333

Ultrastructure, see also Electron microscopy,

- Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisce, P., *et al.* (A) 352
 Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Weldon, J. S., *et al.* (A) 153
 Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddington, J. (A) 138
 Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* . . (A) 682
 Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., *et al.* . . . (A) 503
 Ultrastructure of leprosy phlebitis. Mukherjee, A., *et al.* (O) 571
 Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. (A) 338

Upper Volta,

- Prevalence of secondary dapsone-resistant leprosy in Upper Volta. Pattyn, S. R., *et al.* . . (A) 330

Urine,

- Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* (A) 144
 Urine test for monitoring regular self-administration of dapsone and its application. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. (A) 133

U.S.A.

- 12th Annual Conference of the National Council for International Health (NCIH) scheduled. (N) 128
 Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* (A) 163
 Centers for Disease Control (CDC) position opening. (N) 490
 Dates for major 1986 seminars at Carville. (N) 128
 First U.S. Hansen's Disease Research Conference, 13–15 August 1984, Carville, Louisiana. (A) 154

Hansen's disease in Arizona. Campos-Outcalt, D. and Pust, R. E. (A)	493
Leprosy in the U.S.; risks, recognition, regimens, resources. Pust, R. E. and Campos-Outcalt, D. (A)	666
Leprosy in wild armadillos (<i>Dasypus novemcinctus</i>) of the Texas Gulf Coast. Smith, J. H., <i>et al.</i> (A)	358
Low prevalence of serologic evidence of polyclonal B cell activation among Hansen's disease patients in Seattle. Miller, R. A., <i>et al.</i> (A)	182
New leprosy cases in the U.S. in 1984. (N)	319
Specific health problems of Southeast Asian refugees in middle Tennessee. Dao, A. H., <i>et al.</i> (A)	132
The Heiser Program for Research in Leprosy 1986. (N)	662
Treatment of leprosy in the United States. Levis, W. R. (A)	329
Twentieth Joint Leprosy Research Conference, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 12-13 August 1985. (A)	700
U.S.-Japan Cooperative Medical Science Program,	
Twentieth Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A. (-)	700
Vaccination,	
Antileprosy vaccines—field trials and future prospects. Deo, M. G. (A)	502
Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Smith, D., <i>et al.</i> (A)	363
Effects of <i>Mycobacterium leprae</i> vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. (A)	174
Efficacy of <i>Mycobacterium bovis</i> BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. (A)	697
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. (A)	502
Leprosy—in pursuit of a vaccine. Stewart-Tull, D. E. S. (A)	666
New leprosy vaccine trial. (N)	661
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. (A)	698
Prospects for early diagnosis, immunotherapy, and vaccination for leprosy. Buchanan, T. M. (A)	335
Recombinant vaccinia virus: immunization against multiple pathogens. Perkus, M. E., <i>et al.</i> (A)	698
Simulation of vaccination and resistance in leprosy using an epidemiometric model. Lechat, M. F., <i>et al.</i> (O)	461
Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Mackett, M., <i>et al.</i> (A)	353
Venezuela,	
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., <i>et al.</i> (A)	148
Vietnam,	
Association between leprosy and immunoglobulin allotypes: Gm-A2m and Km frequencies in Vietnamese. de Lange, G., <i>et al.</i> (A)	355
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., <i>et al.</i> (O)	225
Vitamin(s),	
Vitamin E and dapsone-induced hemolysis. Kelly, J. W., <i>et al.</i> (A)	135
World Health Organization (WHO),	
<i>Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group.</i> WHO Tech. Rpt. Ser. 716. (B)	491
..... (N)	663

Results of a World Health Organization-sponsored workshop on monoclonal antibodies to <i>Mycobacterium leprae</i>(A)	682
WHO meeting on multidrug therapy.(N)	126